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In 2013, the Centers for Disease Control and Prevention (CDC) classified Clostridium 
difficile, the bacterium responsible for Clostridium difficile-associated disease (CDAD), as one 
of the three most threatening microorganisms to human health. C. difficile has outpaced 
methicillin-resistant Staphylococcus aureus as the most common healthcare pathogen, and is 
currently the leading cause of antibiotic-associated diarrhea and gastroenteritis-related deaths in 
the United States. Advances in research, national campaigns for healthcare safety, mandated 
disease reporting, legislation for hospital accountability, and the creation of new antibiotics have 
all proven ineffective. The current treatment standards, which have been utilized since the 
discovery of C. difficile pathogenesis in pseudomembranous colitis in the 1970’s, have shown 
waning effectiveness and may actually increase disease recurrence and treatment failure. Interest 
in non-antibiotic alternatives, the evolving understanding of the microbiome as a critical defense 
against pathogens, and the efficacy of oral nutrition supplements in hospitalized populations with 
gastrointestinal disease suggest that targeted nutritional therapy may provide a clinical benefit.  
The intestinal microbiota can be modified by diet, and is critical for immunity, 
metabolism, synthesis of vitamins and other bioactive substances, and resistance against 
pathogens; the microbiota prevents pathogen adherence directly through physical competition, 
and indirectly through the proliferation of anti-inflammatory and antibiotic-like substances. Any 
event that disturbs the microbiome may allow opportunistic pathogens, like C. difficile, to 
adhere, colonize, and produce disease. Therefore, the ability to protect or reestablish the 
microbiota could have vast therapeutic implications.  
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Preliminary data suggest that nutritional status may relate directly to CDAD 
susceptibility. CDAD patients show markedly reduced gastrointestinal microbial diversity, which 
may promote pathological colonization and disease recurrence. Possible methods of repopulating 
the GI tract with healthful bacteria include fecal microbiota transplants and the administration of 
probiotics or prebiotics. The recent popularity of fecal transplants for treatment of GI infections 
is promising, but the process is expensive, unregulated, and aesthetically unappealing. Similarly, 
the ingestion of probiotics has generally shown potential in patients with recurrent CDAD, but 
premature degradation in the upper GI tract can be problematic, and caution is advised for use in 
critically ill or immunocompromised patients. Although prebiotics have the unique advantage of 
being well-tolerated, stable, commercially available, and easily incorporated into the diet, 
clinical studies in this area have been diverse, small, and scarce. Improvements in human studies 
have been attributed to measurable elevations in butyrate, an anti-inflammatory short-chain fatty 
acid byproduct of prebiotic fermentation, as well as an attenuated pro-inflammatory cytokine 
response.  
The first aim of this research was to summarize the existing clinical literature regarding 
prebiotic administration and CDAD with a systematic review. The systematic review search 
identified five studies, yet only three were suitable for inclusion in a meta-analysis. Studies were 
heterogenous, but appeared to slightly, though not significantly, favor prebiotics, as 35/374 
(9.36%) supplemented patients experienced CDAD compared to 64/393 (16.28%) patients in the 
control groups (OR 0.43, P=0.05). Neither side effects nor mortality differed between treatments, 
and further research is needed to determine whether prebiotics may provide a clinical benefit for 
either current or potential CDAD patients. 
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 We next evaluated medical records from Carle Foundation Hospital (CFH) in two 
separate time periods to identify risk factors for CDAD and to determine whether malnutrition 
was related to CDAD prevalence and patient outcomes. A month-long preliminary study 
identified six risk factors (advanced age, admission from another healthcare unit or facility, 
recent hospitalization, and a history of diarrhea or documented CDAD diagnosis within the 
previous year) correlated with CDAD prevalence. These risk factors were then used to separate 
1,277 patients from 2014, and then 973 patients from 2016, into high-risk groups for primary 
studies. Initial analysis revealed that advanced age, previous diarrhea, previous CDAD, 
malnutrition, nutrition consultation requests, and admission from a healthcare facility were 
individually associated with CDAD diagnosis in both 2014 and 2016. However, when multiple 
regression analysis was used to identify predictor variables for CDAD, only previous CDAD 
(OR 111.49, P<0.0001), age ≥65 years (OR 0.43, P=0.004), nutrition consultation requests (OR 
1.70, P=0.04), and BMI (OR 0.96, P=0.02) retained significance in 2014, and only previous 
CDAD (OR 52.95, P<0.0001) and nutrition consultation requests (OR 1.96, P=0.004) in 2016. 
Although malnutrition was not independently associated with CDAD, we believe that it may 
more accurately mirror critical overlooked factors, such as frailty or comorbidity. CDAD 
prevalence did not change between 2014 and 2016 (18.6% vs 17.7%, P=0.57), although both 
malnutrition (10.4% vs 14.7%, P=0.002) and mortality (14.9% vs 18.9%, P=0.01) increased 
within the same time period. While our retrospective studies showed many consistencies 
between the two years and appeared to successfully identify high-risk patients within our sample, 
data restrictions prevented assessment of disease severity. Both the prevalence of malnutrition 
and CDAD were unusually low in comparison with national averages for hospitalized patients. 
Although the exclusive use of a high-risk group prevents comparison with current literature, we 
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intend to use the results of these projects to better direct interventions to prevent CDAD in at-risk 
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CHAPTER 1: INTRODUCTION 
 
Clostridium difficile-associated disease (CDAD) is a debilitating illness with immense 
personal, political, medical, and financial implications. Hospital billing records indicate that over 
9% of CDAD-coded hospital visits result in death compared to 2% for all non-CDAD admissions 
(Walters and Zuckerbraun, 2014). Following the emergence of the epidemic strain, “toxinotype 
III, restriction endonuclease analysis group BI, North American pulsed-field gel electrophoresis 
type NAP1, and polymerase-chain-reaction (PCR) type 027” (NAP1/B1/027), in Pittsburgh in 
2001, CDAD prevalence, severity, and mortality have escalated dramatically. In 2001, C. 
difficile-related hospitalizations accounted for 5.6 per 1,000 discharges, which more than 
doubled to 12.7 per 1,000 patient discharges by 2011 (Steiner et al., 2014). Preliminary data 
predicted that CDAD hospitalizations would reach 14.2 per 1,000 patient discharges by 2013, 
which matched the prevalence provided by the CDC (CDC, 2016), but overestimated the 
approximation of 13.7 per 1,000 patient discharges from the Healthcare Cost and Utilization 
Project (HCUP) (HCUP, 2018). The most recent data released from the HCUP and CDC 
estimate CDAD prevalence to be 14.2 and 14.9 per 1,000 patient discharges, respectively (CDC, 
2017; HCUP, 2018). 
Similarly, mortality attributable to CDAD has increased five-fold, from 2,675 deaths per 
year in 1999-2000 to 14,368 deaths per year in 2006-2007 (Hall et al., 2012). Results from 2015 
indicate that approximately 453,000 new infections arise annually, 29,300 cases result in death 
within 30 days of diagnosis, and half are directly attributable to CDAD (Lessa et al., 2015). 
The cost of CDAD treatment in the U.S. ranges from $6,000-9,000 per uncomplicated 
case, with a conservative national annual estimate of $1-1.6 billion (Scott, 2009). However, some 
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sources have cited annual estimates as high as $4.8 billion for acute care facilities alone 
(Dubberke and Olsen, 2012). The presence of conflicting reports is common in infectious disease 
research, and is usually a product of discrepancies in design, location, strain, magnitude, and 
preferences. Analysis of the Premier Hospital Database, representing three years of patient 
records across 477 diverse U.S. acute care hospitals, revealed that costs for CDAD patients were 
over 40% higher than the average calculated for case-matched controls (Magee et al., 2015). The 
diagnosis added $7,286 per case to CDAD-related costs, even after adjusting for diagnosis-
related groups (DRG), demographics, and hospital characteristics. These data, which only 
included expenses incurred during the index admission, did not capture the cost of significant 
readmission at 30, 60, and 90 days by CDAD patients, and thereby underestimate the total 
healthcare burden.  
In 2009, the U.S. Department of Health and Human Services (HHS) developed an “action 
plan” for combatting seven of the most prominent healthcare-associated infection (HAI) 
measures, which included an ambitious 30% reduction in both CDAD hospitalizations and 
hospital-onset CDAD by 2013 (HHS, 2013). A progress assessment from 2012 indicated that 
results were not on track to meet expectations, and included a 17% increase in CDAD 
hospitalizations and a mere 2% decrease in hospital-onset CDAD. Although hospital-onset 
CDAD decreased by 8% from 2011 to 2014, the 4% increase observed from 2013-2014 
mitigated preliminary progress, and may arguably signal an ongoing upward trend. The current 
version of the HHS Action Plan reiterates the same objective with a new timeline, and projects a 
30% reduction in CDAD from the 2015 baseline by 2020.  
Impending changes in legislation, healthcare, and demographics make the failure to 
contain CDAD uniquely problematic. Although it has yet to be adopted as a non-reimbursable 
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diagnosis, CDAD-related healthcare penalties are planned for FY2017 through Value-Based 
Purchasing (VBP), established by the 2011 Patient Protection and Affordable Care Act, and the 
Hospital Acquired Condition Reduction Program (HACRP) in 2015 (2010). VBP, a pay-for-
performance initiative, issues payment to acute care hospitals based on quality and patient 
satisfaction, whereas HACRP withholds Medicare reimbursement from hospitals with the 
highest infection rates. These imminent Medicare revisions will have inordinate financial 
implications in regard to the anticipated shift in the national age structure. The incidence of 
CDAD is nearly nine times higher in patients over the age of 65, and 93% of CDAD deaths 
occur among patients in this age group (Kochanek, 2011). Elderly persons are expected to 
comprise over 20% of the U.S. population by the year 2030, and illnesses that disproportionately 
affect Medicare beneficiaries will likely demand unprecedented resources and care (Ortman et 
al., 2014).  
C. difficile pathogenicity 
As many HAIs have subsided with concomitant advances in research, patient education, 
and improved quality care, CDAD rates have remained high, with infections arising from both 
endemic and epidemic strains (Yakob et al., 2015). C. difficile is a resilient and effective 
pathogen that disproportionately targets vulnerable individuals. Advanced age, antibiotic use, 
recent healthcare facility exposure, and a history of diarrhea or CDAD within the previous year 
all increase CDAD risk (Cooper et al., 2013) (Table 1.1).  
CDAD acquisition requires both a contaminated environment and a susceptible, 
compromised host. Most frequently, host colonization is precipitated by oral antibiotic use, 
which displaces the protective intestinal microbiota and permits the adherence of opportunistic 
pathogens. Following ingestion of C. difficile endospores, bacteria germinate in the small 
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intestine, and adhere to epithelial cells and elaborate inflammatory and destructive toxins in the 
colon. Infected patients may experience a range of symptoms from watery diarrhea to fulminant 
colitis and sepsis. Paradoxically, antibiotic regimens, which facilitate C. difficile colonization 
and infection, are the current treatment standard. The Infectious Disease Society of America 
(IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines recommend 
restricting antimicrobial use to curtail CDAD risk (Cohen et al., 2010). For patients with active 
CDAD, IDSA/SHEA advises discontinuation of the inciting antibiotic, followed by 
administration of either metronidazole, vancomycin, or fidaxomycin. Treatment failures and 
recurrences are common, with a systematic review of over 7,000 patients reporting means of 
22.3 and 22.1%, respectively (Vardakas et al., 2012).  
The heightened recognition of antimicrobial resistance throughout most of the world has 
reinforced pre-existing concerns about excessive antibiotic use. The World Health Organization 
(WHO) currently urges antibiotic stewardship, regulation, and “innovation, research, and 
development” for alternative options (WHO, 2015). Several non-antibiotic therapies have shown 
promise in preliminary studies, and recent estimates indicate that 30-50% of antibiotics 
prescribed within hospitals and over 50% of those prescribed by outpatient facilities are either 
unnecessary or inappropriate (Lessa et al., 2015). Impaired gut colonization resistance is a 
hallmark of antibiotic treatment, and although these medications may interrupt vegetative C. 
difficile, their elimination of microbial diversity could promote future pathological colonization 
(Pérez-Cobas et al., 2014). Furthermore, even very specific and narrow-spectrum antibiotics may 
not eliminate the persistence of C. difficile spores. Some studies have suggested that antibiotic 
treatment is the main cause of CDAD recurrence, a phenomenon observed in approximately one 
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in five successfully treated individuals, an estimated 83,000 first-time episodes each year 
(Shields et al., 2015). 
The inability to regulate primary CDAD infection and recurrence highlights the 
importance of disease prevention over management. Prophylactic therapies that systematically 
reinforce or restore commensal-mediated pathogen resistance may prove to be more valuable 
than additional microbial depletion. Furthermore, microbiota manipulation through 
pharmacological or dietary means provides an intuitive alternative to standard antibiotic 
treatment and represents an important mechanism through which nutrition directly impacts 
disease risk and development. 
Introduction to malnutrition 
The concept of “iatrogenic malnutrition” was publicized by the 1974 article, “The 
Skeleton in the Hospital Closet” (Butterworth). The issues that Charles Butterworth mentioned 
more than 40 years ago—deficiencies in nutrition education, the depersonalization of healthcare, 
and an inability to translate basic research into clinical improvements—still resonate with 
modern medicine. Malnutrition is severely underdiagnosed in hospitals due to a lack of education 
among medical staff and underutilized or unavailable dietetic resources (Gout et al., 2009).  
Approximately 40% of all patients in acute care facilities and between 29-61% of elderly 
patients are affected by malnutrition (Corish and Kennedy, 2000). In developed countries, one in 
three patients are malnourished upon hospital admission (Barker et al., 2011); two-thirds of these 
patients will experience a further decline in nutritional status throughout the hospital stay due to 
illness, medical complications, and poor provision or access to food (Somanchi et al., 2011). 
Among patients who are adequately nourished upon admission, one-third will become 
malnourished during hospitalization (Braunschweig et al., 2000). The onset and exacerbation of 
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malnutrition during hospitalization have complex physiological, emotional, and social etiologies. 
Weight loss and reduced lean body mass can reflect the heightened metabolic demands and 
unique psychological pressures associated with inflammation, isolation, and inactivity (Ahmed 
and Haboubi, 2010); anorexia and anhedonia may arise from polypharmacy, a lack of social 
support, environmental instability, depression, or anxiety (Jansson et al., 2007). Malnutrition is 
inextricably linked to many aspects of physical and mental health. It is, therefore, critical to view 
the identification and treatment of iatrogenic malnutrition as an interdisciplinary issue.  
Definitions and diagnosis 
The diagnostic characteristics for adult malnutrition recently established by the American 
Society for Parenteral and Enteral Nutrition/Academy of Nutrition and Dietetics (ASPEN/AND) 
consensus statement include insufficient energy intake, weight loss, loss of muscle mass, loss of 
subcutaneous fat, localized or generalized fluid accumulation (edema), and decreased functional 
status (White et al., 2012). Although the term “malnutrition” technically describes any nutritional 
imbalance, it will be used synonymously with undernutrition for the purpose of this review. 
Effects of malnutrition 
 Malnourished patients often require more intensive care than their adequately nourished 
counterparts and risk severe injury due to fatigue, muscle wasting, and impaired physical 
capacity; hospital-associated deconditioning, a functional decline associated with acute 
hospitalization, almost exclusively affects malnourished individuals. A 2014 study revealed that 
88% of elderly inpatients with hospital-associated deconditioning had a malnutrition diagnosis, 
while the remaining 12% were considered at-risk (Wakabayashi and Sashika, 2014). Expectedly, 
malnourished patients are likely to incur longer hospitalizations and accrue higher treatment 
costs (Correia and Campos, 2003; Lim et al., 2012). Even patients at-risk for malnutrition are 
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subject to extended stays and higher costs (Chima et al., 1997; Thomas et al., 2016). 
Remarkably, these extra personal and financial resources are not correlated with better outcomes. 
Retrospective data from 25 different hospitals detected elevated costs ($228 vs $138), mortality 
(12.4% vs 4.7%), complications (27% vs 17%), and length of stay (LOS) (16.7 days vs 10.1 
days) for malnourished patients (Correia and Waitzberg, 2003). Similarly, a large Singapore 
case-control hospital study concluded that malnutrition was associated with a two-day increased 
LOS, 24% higher treatment costs, a 200% increase in the likelihood of unplanned 15-day 
readmission, and a four-fold and three-fold rise in mortality after one and three years, 
respectively (Lim et al., 2012). Less pronounced disparities were reported in an analysis of the 
3,122-patient 2010 Australasian Nutrition Care Day Survey, which controlled for age, gender, 
diagnosis, and disease severity. A 50% increase in LOS and doubled mortality rates were 
observed for malnourished individuals, though readmission rates were only modestly increased 
(Agarwal et al., 2013). 
The importance of nutritional care in ensuring positive outcomes is exemplified by the 
successes of clinical supplementation trials. Interventions have improved quality of life and 
decreased mortality, complications, and costs.  A Cochrane database review revealed that oral 
protein and energy supplements reduce mortality risk among older undernourished people (RR 
0.79) and decrease complications (RR 0.86) (Milne et al., 2009). A meta-analysis of 11 
randomized controlled trials demonstrated lower mortality in patients receiving oral nutrition 
supplements (OR 0.61), while an analysis of seven trials confirmed reduced complications in 
supplemented groups (OR 0.31) (Stratton, 2003).  
Malnutrition, infection, and immunity 
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Within the last few decades, model diseases like tuberculosis and HIV have highlighted 
the complex interdependence among infection, malnutrition, and immunity. Although CDAD 
and other diarrheal infections have a well-documented history of causing malnutrition (Guerrant 
et al., 2008), we hypothesize that the reverse scenario is equally plausible; modifications in gut 
microbiota and the immunological aberrations that characterize malnutrition may promote 
pathological colonization and illness, especially in susceptible, high-risk individuals.  
Reciprocity between malnutrition and disease is not a particularly novel concept; the 
1968 publication, Interactions of Nutrition and Infection, published by the WHO, recounts 
numerous studies detailing the relationship among malnutrition, bacterial infection, and diarrheal 
diseases (Scrimshaw, 1968). Excerpts from cited research affirm that diarrhea is more prevalent 
in malnourished children (Garcia Erazo, 1960), susceptibility to intestinal pathogens is increased 
by nutritional deficiency (McKenzie, 1940), and morbidity is three times greater and mortality is 
seven times greater in malnourished children than in those who were adequately nourished 
(Oropeza, 1963). 
CDAD and malnutrition disproportionately affect the same groups, including hospital 
patients, long-term care facility residents, and elderly or immunocompromised individuals. 
Advanced age, one of the most substantial risk factors for CDAD development, is independently 
associated with several physiological manifestations of malnutrition, including hypochlorhydria, 
slowed intestinal transit, gut-leakiness, and tempered immunity. Furthermore, hospitalized 
elderly are often at greater risk due to weakened masticatory ability, altered sensory perception, 




The composition of microbial communities within the gut vary with age, weight, 
exercise, drug use, diet, and health. In general, genetic diversity has been correlated with health, 
whereas lower diversity is observed in many disease states (Scott et al., 2015). Elderly hospital 
patients exhibit elevated proportions of bacteroides and lower bacterial diversity, total bacteria 
counts, bifidobacteria, and clostridium cluster IV when compared to healthy young controls 
(Zwielehner et al., 2009), and a reduced Firmicutes to Bacteroidetes ratio is observed among 
elderly individuals and those who have experienced recent weight loss (Ley et al., 2006). 
Increased risk among the elderly and negligible risk in infants may be associated with 
microbiome modification throughout the life cycle. Many studies have shown a correlation 
between nosocomial infections and malnutrition in this age group (Gamaletsou et al., 2012; 
Paillaud et al., 2005; Potter et al., 1995; Rothan-Tondeur et al., 2003), and notable research by 
Schneider et al. (2004) confirmed that even moderate malnutrition is an independent risk factor 
for nosocomial infection.  
The mechanisms through which malnutrition promotes gastrointestinal infection involve 
the compromised efficacy of the gut-immune barrier and significant modifications in gastric pH, 
immune function, gut architecture, and microbial communities. In the stomach, reduced acid 
output enables the passage of pathogens into the small intestine (Gilman et al., 1988), which is 
likely responsible for the elevated CDAD risk observed among patients taking proton pump 
inhibitors (Deshpande et al., 2012). Lymphopenia may further impair host defenses and inhibit 
bacterial clearance as malnutrition reduces intestinal weight, particularly in gut-associated 
lymphoid tissue (Cole, 1999). Macroscopic physical remodeling and intestinal adaptation, 
including mucosal atrophy, tight junction impairment, and loss of barrier function (Shaw et al., 
2012) increase gut permeability and bacterial translocation (Van Der Hulst et al., 1998). 
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Pathogen adherence and colonization are facilitated by the depletion of commensal microbiota, 
as well as restricted intestinal motility and prolonged transit time, which are both products of low 
enteral intake. 
Correlational studies between malnutrition and CDAD  
While many articles list malnutrition as a risk factor for CDAD development (Lo 
Vecchio and Zacur, 2012), research to support this claim is limited. Similar risk factors, as well 
as the observation that patients with CDAD are often malnourished, provide evidence for 
association, but have yet to establish directionality. An extensive review of nearly 900,000 
patients determined that previous weight loss or malnutrition tripled the odds of acquiring C. 
difficile enterocolitis (Fry et al., 2010). This correlation has been corroborated by others, and was 
initially observed in a retrospective analysis of 172 Veterans Affairs hospitals in 2001 (Buchner 
and Sonnenberg, 2001). Another retrospective evaluation of 65 patients with CDAD reported a 
mean weight loss of 9% upon admission; the authors suggested that the weight loss constituted 
malnutrition and, therefore, concluded that CDAD patients are often malnourished (Barlow and 
Howell, 2010). Malnutrition may negatively affect prognosis for CDAD patients, perhaps 
independently of previous illness and comorbidities. In a pilot study from the United Kingdom, 
54% of CDAD patients were classified as malnourished (defined as a MUST score of 2) at the 
time of diagnosis, and exhibited increased mortality and LOS compared to controls (Wong et al., 
2009). Preliminary data from a later study yielded similar results, as CDAD patients had a 
greater rate of malnutrition at admission, higher mortality, more antibiotic exposure, and a longer 
LOS than uninfected patients (Monge et al., 2013).  
In contrast to the studies that addressed protein-energy malnutrition and weight loss, 
recent work has acknowledged a novel relationship between CDAD and vitamin D status. In 
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2010, vitamin D deficiency was associated with elevated costs for CDAD patients (Youssef et 
al., 2010). Outpatients and inpatients with low levels of serum 25(OH)D accrued 1.5 and 5.7 
times the cost of infected controls, respectively, which suggests that nutritional inadequacy 
exacerbates resource utilization among CDAD patients. Furthermore, Wang et al. (2014) 
reported that patients with low vitamin D levels were nearly five times more likely to maintain 
infection, and CDAD resolution was independently predicted by normal vitamin D levels. In this 
study, low vitamin D levels, as well as advanced age, were shown to independently predict 
disease recurrence. Retrospective analyses have identified an inverse relationship between 
vitamin D status prior to hospital admission and hospital-onset CDAD (Quraishi et al., 2015). 
The association was previously documented in a study of inpatients with Inflammatory Bowel 
Disease, which measured lower vitamin D levels among both CDAD patients and case-related 
deaths (Ananthakrishnan et al., 2014). In a computed tomography study, severe disease, 
represented by colitis, was more common in patients with low 25(OH)D3 (van der Wilden et al., 
2015). While these vitamin D studies have strengthened the correlation between malnutrition and 
CDAD, causality remains indeterminable due to the preliminary, correlational, and retrospective 
nature of the available evidence. 
Conclusion 
CDAD and malnutrition are critical concerns for hospitals and significantly contribute to 
morbidity, mortality, and healthcare costs. To date, the role of nutritional status in CDAD 
susceptibility and severity remains unclear. Prior research limitations include the low detection 
of malnutrition among hospital patients, inconsistencies in nutritional screening and assessment, 
the recent emergence of C. difficile as a prominent healthcare pathogen, and the inability to 
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obtain comprehensive and accurate data. The completion of large-scale, well-controlled 
prospective trials is needed to determine causation.  
In clinical studies, nutritional supplementation has consistently reduced costs, 
complications, and mortality among high-risk hospitalized populations. Susceptibility to 
infection in malnourished patients may be attributed to immune system impairment, aberrations 
in gut microbiota, and increased environmental exposure to opportunistic pathogens. 
Accordingly, therapies that strengthen immunity, reduce inflammation, reinforce microbiota, or 
minimize LOS are of particular interest. Enhanced antimicrobial vigilance throughout the world 
and the evolving appreciation for the protective role of commensal bacteria emphasize the 
importance of non-antibiotic treatment alternatives, while high CDAD recurrence rates highlight 
the need for disease prevention rather than management. A nutrition-based solution, including 
supplementation, improved dietetic resources, and the assurance of adequate provisions during 
hospitalization may improve patient outcomes and provide a practical, safe, and cost-effective 
alternative for CDAD prevention. 
TABLE 
 
Table 1.1 Risk factors associated with Clostridium difficile-associated disease (CDAD) 
Advanced age (≥ 65 yr) 
Admission from another healthcare facility (includes nursing home, jail, etc.) 
Hospitalization within 90 days of current hospitalization 
Antibiotic use within 90 days of current hospitalization 
Clinical documentation of diarrhea within one year of current hospitalization 
Positive CDAD diagnosis within one year of current hospitalization 







CHAPTER 2: LITERATURE REVIEW 
 
Malnutrition in hospital patients 
The 2010 data from HCUP reported that 3.2% of hospital discharges in the United States, 
or 1,248,680 patients, had malnutrition diagnoses. A comprehensive analysis by Corkins et al. 
(2014) sought to determine the validity of these diagnoses and examined commonalities among 
patients. Patients diagnosed with malnutrition, compared to patients who were not diagnosed, 
tended to be older (64.8 years vs 47.8 years; P<0.001), male (53.1% female vs 57.8% male; 
P<0.001), below the 50th percentile for income (57.9% vs 55.0%; P=0.004), and list Medicare as 
their primary payer (P<0.001). Whites made up the vast majority of both groups, and differences 
in racial composition were observed between diagnosed and non-diagnosed groups (P<0.001). 
Malnourished patients were more likely to be discharged from private, for-profit hospitals 
(P=0.002), Southern or Midwestern hospitals (P=0.003), and hospitals within a professional 
network (71.4% vs 66.5%; P = 0.005). Expectedly, and in accordance with other data, patients 
who received malnutrition diagnoses experienced an extended length of stay (LOS) (12.6+0.5 
days vs 4.4+1 days; P<0.001), accrued higher costs ($26,944 vs $9,485; P<0.001), were more 
likely to enter the hospital emergently (80% vs 60%; P<0.001), but less likely to have a routine 
discharge (28.8% vs 71.2%; P<0.001). Importantly, malnourished patients were two times as 
likely to be discharged to home health care (19.8% vs 10.4%; P<0.001), and five times more 
likely to be discharged to death (8.8% vs 5.7%; P<0.001).  
Patients with malnutrition diagnoses experienced 27 of 29 comorbidities more frequently 
than undiagnosed patients. Some comorbidities were expected for the diagnosis (weight loss, 
fluid and electrolyte disorders, deficiency anemia), some malnutrition diagnoses could likely be 
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attributed to a comorbidity or its treatment (diabetes, lymphoma, metastatic cancer, AIDS, 
alcohol abuse, liver disease, peptic ulcer disease), and the etiology for others was unclear, or 
suggested a more malicious possibility (hypertension, chronic pulmonary disease, renal failure, 
congestive heart failure, neurological disorders, depression, hypothyroidism, coagulopathy, 
peripheral vascular disease, metastatic cancer, paralysis, psychosis, valvular disease, pulmonary 
circulation disease, rheumatoid arthritis). Predictably, patients with the malnutrition diagnosis 
had twice as many International Classification of Diseases, Ninth Revision (ICD-9) codes listed 
in their charts than patients without a malnutrition diagnosis (14.8 codes vs 7.9; P<0.001). 
Surprisingly, parenteral (PN) or enteral (EN) nutrition were only provided to 13.4% of patients 
with a malnutrition diagnosis, with 8.9% receiving PN, 5.2% receiving EN, and 0.7% receiving 
both PN and EN.  
The low number of patients with a malnutrition diagnosis is consistent with other reports, 
which indicate that this condition is vastly under-diagnosed among hospital patients nationwide. 
Although cause and effect cannot be determined in this study, these data suggest that 
malnourished individuals are high risk patients and, in general, much sicker than their 
counterparts. The listing of Medicare as the primary payer for the malnourished group is 
significant, as these patients accounted for three times the cost and LOS of the undiagnosed 
group. Elevated costs and LOS are often required for malnourished patients, and will be 
discussed in a future section. Another commonality among malnourished patients is increased 
mortality, which is also represented by these data. It would be remiss to presume that nutritional 
status is the only contributor to the observed disparities between groups, especially when 
measured parameters imply the possibility of socioeconomic or racial bias; essentially, these data 
are valuable, as they illustrate the connection among malnutrition, immunity, healthcare delivery, 
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and lifestyle, and serve as a reminder that health is a multifaceted outcome. The difference in the 
prevalence of malnutrition diagnoses among hospital types and geographical regions underlies 
the need for education, diagnostic consistency, and action. The increase in patients coded for 
malnutrition in recent years, coupled with 91.7% of the malnourished group compared to 0.6% 
of the other group experiencing weight loss, suggests that malnourished patients were probably 
diagnosed correctly, and that errors are most likely from omission. 
Nutrition screening and assessment 
Laboratory-based methods of nutritional assessment are considered archaic by some, and 
the objective assessment of nutritional status has been historically problematic. The variability in 
malnutrition prevalence throughout the world greatly reflects not only inherent geographical, 
cultural, genetic, and socioeconomic differences, but also the need for mandatory healthcare 
screening, updated methodology, and universally accepted standards. The ASPEN/AND and the 
European Society for Clinical Nutrition and Metabolism (ESPEN) consensus statements criticize 
earlier methods, particularly the applicability of biochemical parameters for nutritional 
assessment (Cederholm et al., 2015). Serum protein measurements such as albumin, prealbumin, 
transferrin, retinol binding protein, C-reactive protein, and creatinine have not yielded consistent, 
accurate, and useful results in clinical practice (Bresnahan and Tanumihardjo, 2014), and may 
more accurately assess the presence of inflammation than malnutrition (Banh, 2006). The use of 
serum biomarkers for diagnosing malnutrition is particularly confounding for individuals with 
known comorbid infectious or inflammatory conditions, as low-level inflammation, immune 
senescence, and regular medication use likely exacerbate the potential for interpretive errors, 
particularly in geriatric populations. While the use of WBC, albumin, and creatinine 
measurements have fallen out of favor for nutritional diagnoses, they serve as valid predictors of 
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CDAD-related disease severity and mortality (Bloomfield et al., 2012; Henrich et al., 2009; 
Moshkowitz et al., 2007). 
In healthcare settings, nutritional status is evaluated through patient screening and 
assessment. The initial screening process identifies patients at risk for malnutrition and 
determines whether further comprehensive assessment is warranted. A 2005 review identified 
over 70 published nutrition screening tools and reviewed 35 after exempting tools that required 
complex anthropometry, significant biochemical or intake analysis, or were designed for aged 
populations (Green and Watson, 2005). Due to the plurality of acceptable methods, selection of 
the proper tool requires a fairly nuanced appreciation of their differences. Some tools are 
designed to verify nutritional status or identify patients who would potentially benefit from 
nutritional intervention, while others specifically predict risk, resource utilization, or patient 
outcomes. The limits and categories used for analysis, as well as the addition and weighting of 
non-nutritional items, are specific to each tool, and may, therefore, inconsistently approximate 
risk, even among identical patients (Elia and Stratton, 2012). The lack of a gold standard and low 
concurrent validity among tests complicates the screening process, both in terms of clinical care 
and nutrition-based research. 
Nutritional assessment requires information about patient history, food intake, weight, 
and, occasionally, height and body composition. Analysis of one or more of these factors is not 
always possible, and criteria that evaluate changes over time are ineffectual without proper 
foresight and baseline documentation. Among elderly patients, age-related physical and 
cognitive constraints may impair assessment (Oliveira et al., 2009). Naturally occurring spinal 
compression, the presence of disabilities and illnesses that prevent upright posturing, inherent 
memory impairments, and degenerative disease processes can obscure or prevent the appropriate 
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interpretation of necessary parameters. In addition to physical confounders, technical and human 
errors or limitations can interfere with the collection of information relevant to treatment and 
research.  
Biomedical research often relies on observational data or convenience samples, 
especially in preliminary phases or when interventional trials are unethical or unfeasible. This 
type of study is inexpensive, expedient, informative, and poses minimal risk, but is dependent on 
consistent, objective, and thorough records. Retrospective nutritional studies may utilize 
unconventional surrogate criteria, including the amount of weight lost, a body mass index 
calculation, basic anthropometry, and subjective patient accounts to infer a deficiency diagnosis 
when records do not explicitly address nutritional status. In summary, screening discrepancies, 
interpretation errors, and unavailable or inaccurate information may contribute to patient 
misclassification, provider uncertainty, and contradictory data.  
The diagnosis and documentation of malnutrition are important in terms of patient care, 
as well as cost recovery. The diagnosis by physicians and subsequent grouping of patients into a 
Diagnosis Related Group (DRG) for insurance or Medicare reimbursement purposes may cite an 
additional complication or comorbidity (CC) or major complication or comorbidity (MCC) for 
additional payment when a qualifying secondary diagnosis is present (Lowry et al., 2015). 
Malnutrition, depending on severity, is either a MCC (kwashiorkor, nutritional marasmus, severe 
protein-calorie malnutrition) or CC (other or unspecified protein-calorie nutrition, and cachexia, 
wasting due to chronic illness). In many cases, as long as malnutrition is adequately documented, 
an institution can provide treatment, and not be held accountable for related expenses. Although 
malnutrition is vastly underdiagnosed, the abuse of malnutrition coding, most frequently as a 
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MCC, reflects a sincere need to accurately document cases and follow through with appropriate 
interventions. 
CDAD acquisition and onset 
For some adults and most infants, C. difficile is a normal component of the gut 
microbiota. Approximately 3% of healthy adults and up to 60-70% of newborns and infants are 
asymptomatic C. difficile carriers (Ghose, 2013). For hospitalized adults, 8% are estimated to 
carry C. difficile upon admission (Zacharioudakis et al., 2015). All colonized individuals serve as 
bacterial reservoirs and facilitate pathogen transmission. CDAD is typically acquired through 
accidental ingestion of endospores either within a contaminated environment, or through contact 
with contaminated people, and endospores have even been recovered in samples of hospital food 
(Koo, 2012). Endospores are uniquely resilient, as they resist ethanol degradation, desiccation, 
and can persist on hard surfaces for up to five months (Gerding et al., 2008). In addition to being 
resistant to conventional disinfection techniques, bacteria are inadvertently spread by visitors, 
patients, and hospital personnel. The anaerobic, spore-forming bacteria are transmitted via the 
fecal-oral route. After endospores bypass the acidic stomach, they germinate into vegetative 
bacteria in the small intestine. The two toxins traditionally produced by C. difficile, toxin A and 
toxin B, promote the release of inflammatory cytokines and initiate tissue destruction through 
disruption of the actin cytoskeleton and disturbance of epithelial cell tight junctions in the colon 
(Carter et al., 2010).   
The onset of CDAD typically occurs after 48 hours of hospitalization, and a healthcare-
associated case may not appear until up to four weeks following discharge. Healthcare-
associated infections can have either a healthcare or community onset; only 24% of all CDAD 
cases occur during hospitalization, while the vast majority occur among patients who were 
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recently discharged (Lessa et al., 2015). The release of undiagnosed patients, unsuccessfully 
treated patients, and asymptomatic carriers into the community, including outpatient settings and 
long-term care facilities, has resulted in the emergence of community-associated cases (Gupta 
and Khanna, 2014). Infection data for 2014 were comprehensively modeled with demographic, 
epidemiologic, and economic factors to emulate a “societal perspective” of CDAD burden, 
which predicted a community-associated CDAD cost of $725 million (13.3% of the predicted 
total) (Desai et al., 2016). 
A retrospective study of 400 hospital patients with CDAD reported that 46.1% and 33.3% 
of cases were expected to have originated in long-term care facilities and the community, 
respectively (Garg et al., 2013). The remaining 20.6% were classified as “hospital-acquired”. 
Patient classification was determined by where each individual lived prior to admission, i.e., 
either a long-term care facility or the community, and patients were considered to have hospital-
acquired CDAD if they exhibited symptoms and had a positive C. difficile test no earlier than 
three days after admission. Numbers in this case are likely skewed away from hospital-acquired 
cases, as it was defined as having been acquired at least three days after admission, and the study 
design excluded all patients with an overnight hospital stay within the last three months or with a 
history of antibiotics within eight weeks leading up to admission. Regardless of the composition 
of groups, these data are significant, as they show that both long-term care facilities and the 
community are important transmission zones. Additionally, only 18.2% of the presenting 
complaints were diarrheal, the primary symptom associated with CDAD. Instead, patients most 
commonly reported abdominal pain, fever, or altered mental state. Patients in the hospital-
acquired group accounted for the majority of intensive care visits and deaths, which comprised 
24.4% and 6.2% of the subgroup. Results suggest that CDAD from long-term care facilities and 
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the community may present without standard signs, and may follow a less severe clinical course. 
Another caveat not mentioned by authors is that higher mortality in the hospital-acquired group 
is not entirely unpredicted, as hospital acquired CDAD, by definition, takes at least 48 hours to 
develop and, therefore, could not be the primary admitting diagnosis.  
CDAD in long-term care facilities 
The reason for the high prevalence of CDAD in long-term care facilities is a combination 
of excessive antibiotic use and environmental contamination. Up to 90% of hospitalized patients, 
42% of nursing home residents, and 25% of hospice patients, receive antibiotics within the last 
few weeks of life (Juthani-Mehta, 2015). In very elderly and dying patients, antibiotics are 
regularly given as a life-extending intervention, even for patients without clinical symptoms 
suggestive of a bacterial infection. The problem of transmission in long-term care facilities 
cannot be underestimated. In a Cleveland, OH long-term care facility, the majority of residents 
tested positive for C. difficile (Riggs et al., 2007). Excluding the 18 control patients with active 
CDAD, 51% of the remaining 68 patients were found to be asymptomatic carriers, testing 
positive for bacterial colonization, but without experiencing symptoms. Among the carriers, 37% 
carried especially virulent, epidemic strains. Environmental contamination was high, and within 
patient rooms, positive cultures were found for 78%, 59%, and 24% of patients with active 
CDAD, carriers, and non-carriers, respectively. Skin contamination, similarly, was found for 
78%, 61%, and 19% of CDAD patients, carriers, and non-carriers, respectively. Within the six-
month follow-up period, 20% of the asymptomatic carriers had developed CDAD. This study is 
significant for two reasons; it shows that C. difficile is easily transmissible by touch and 
environmental contamination, and that asymptomatic carriers may still acquire CDAD, likely 
due to infection by a strain other than the one they were initially colonized with.  
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CDAD in the community 
Another atypical environment for C. difficile transmission is within the community. 
Although community-associated CDAD accounts for only 150,000 out of nearly a half million 
cases, most of these infected patients report indirect healthcare exposure. In a study of 984 
documented community-associated CDAD cases, 82% of respondents reported at least one visit 
to an outpatient healthcare setting in the 12 weeks prior to diagnosis (Chitnis et al., 2013). This 
finding suggests that at least some community-associated CDAD may still be outpatient 
healthcare related, particularly since eradicating C. difficile spores often requires noxious 
cleaning agents and methods rarely used outside of hospitals. While community-associated 
CDAD is less likely to result in recurrence and mortality than the healthcare-associated type, it 
remains an important avenue for disease transmission. 
CDAD in hospitals 
Reports from the Agency for Healthcare Research and Quality indicated that healthcare-
associated CDAD affected eight out of every 1000 (0.80%) hospital discharges in 2008 (Lucado 
et al., 2012) and 13.5 out of every 1000 (1.35%) hospital discharges in 2012 (Steiner et al., 
2014). A 2015 meta-analysis of 19 studies estimated that the risk of infection in non-colonized 
patients was 3.4% (Zacharioudakis et al., 2015). Infection risk was 5.9 times higher in patients 
who were colonized with C. difficile upon hospital admission than non-colonized patients, which 
refutes the 1998 study by Shim et al. that reported a protective carrier status for further C. 
difficile diarrhea (Shim et al., 1998). The pervasiveness of C. difficile endospores within 
healthcare environments leave the sickest and highest risk individuals remarkably vulnerable to 
infection. Beyond traditional risk factors for CDAD, the literature has disputed the validity of 
many others, including gender, race, LOS, proton pump inhibitor use, recent gastrointestinal 
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surgery, malnutrition, and the presence of severe comorbid conditions (Lo Vecchio and Zacur, 
2012). 
Risk Assessment 
A thorough review of the literature revealed many methods of assessing CDAD risk. 
Among the risk assessment tools were Horn’s index, the Waterlow assessment score, and the 
Ratio of white cell count on the day of the positive C. difficile toxin test to two days previously, 
as well as the Urea, White cell count and Albumin on the day of the positive C. difficile toxin test 
(RUWA) system, among others. These indices generate a score based upon an individual’s basic 
laboratory values or medical history, which then is used to estimate the likelihood that the 
individual will acquire the disease.  
Horn’s index ranks a patient on a scale of increasing disease severity, and requires that a 
qualified clinician rate the severity of the underlying disease, giving the patient a score of 1 for 
single mild illness, 2 for more severe illness but when uncomplicated recovery is expected, 3 for 
major illness or complications or multiple conditions requiring treatment, or 4 for a catastrophic 
illness that may lead to death (Arora et al., 2011). This high-throughput model is based upon the 
expectations of a disease course, and is highly dependent upon the observer. The Waterlow 
score, a screening tool initially created for the prediction of pressure ulcer formation, requires 
data for several parameters that are unlikely to be noted in a chart, including tactile evaluation of 
skin integrity, food consumption, and a five point mobility scale (Tanner et al., 2010). Unlike the 
other tools, the RUWA system relies exclusively on laboratory testing conducted at the time of 
laboratory diagnosis, and then again two days later (Drew and Boyle, 2009). 
The primary issue with these methods is that patients may be infected before they are 
identified. Infection can occur at any time, and symptoms may not appear for up to four weeks 
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following infection. In a study with 247 CDAD positive cases, 148 (60%) were classified as 
healthcare-associated with hospital onset, an additional 77 patients had developed CDAD within 
30 days of discharge, and the remaining 22 patients were diagnosed within 60 days following 
hospital discharge (Dubberke et al., 2009). The community-onset healthcare-associated CDAD 
rate after both 30 days (2.4/1,000 patient-days, P<0.01), and 60 days (2.6/1,000 patient-days, 
P<0.01) post-discharge, were significantly higher than the healthcare-associated hospital-onset 
CDAD rate (1.6 cases/1,000 patient-days). Infection rates between patients assessed 30 days vs 
60 days after discharge did not differ (P=0.31). 
Early intervention prevents the further transmission of bacteria among other patients and 
the introduction of bacteria into the community following hospital discharge. Cooper et al. 
(2013) introduced a risk factor-based system into the hospital’s electronic medical record (EMR) 
software to help identify patients with a predisposition to CDAD. The screening tool was based 
on a prospective list of risk factors, which was created using the hospital’s data, combined with 
elements from CDAD literature. From the list of possible risk factors, regression identified four 
significant risk factors for CDAD, including the presence of diarrhea (P<0.0001), prior CDAD 
(P<0.0001), multiple antibiotic use (P<0.0001), and admission from another health care facility 
(P<0.0001). The positive predictive value, or proportion of true positives, and negative predictive 
value, or proportion of true negatives, were calculated as 4.9 and 99.9%, respectively. Similarly, 
sensitivity, or the ability to detect all diseased individuals, and specificity, the ability to detect all 
non-diseased individuals, was 91.6 and 87.0%, respectively. The model identified 92.9% of 




The clinical presentation of CDAD is highly variable, and ranges from severe diarrhea to 
toxic megacolon and fatal sepsis. The course and severity of the disease ultimately determines a 
patient’s prognosis. Basic laboratory analysis may be used to stratify disease severity, as 
leukocytosis, hypoalbuminemia, and elevated creatinine and C-reactive protein have been 
correlated with worse outcomes (Pépin et al., 2004). In a retrospective review conducted by 
Henrich et al. (2009), the maximum leukocyte count was higher in patients with severe CDAD, 
and more patients with severe disease had minimum albumin <2.5g/dL (OR 3.4), maximum 
leukocyte count >20,000 cells/mL (OR 2.8), and maximum creatinine >2.0 mg/dL (OR 2.5). 
Although low albumin, elevated leukocytes, and high creatinine were associated with severe 
disease in this study, a positive computed tomography (CT) scan for intestinal inflammation was 
the most reliable marker (OR 13.5).  
Serum markers may not only reflect disease severity, but may also predict mortality. In 
elderly patients with Pseudomembranous colitis, an aggressive clinical manifestation of CDAD, 
hypoalbuminemia (P=0.02) and increased white blood cell (WBC) count (P=0.009) were 
associated with high mortality (Moshkowitz et al., 2007). A 2012 systematic review conducted 
by Bloomfield et al. (2012) concluded that risk markers for CDAD mortality included WBC, 
serum creatinine, and serum albumin, but not other commonly considered variables such as 
hematocrit or diarrheal severity. Importantly, many methodologies and therapies that once were 
considered the gold standard are no longer effective due to treatment failures, disease recurrence, 
and concerns about antibiotic resistance.  
Recurrent CDAD 
Disease recurrence is extremely common among patients who have been successfully 
treated for CDAD, and often follows a more expensive, aggressive, and indolent course than the 
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initial infection. It is characterized by the resolution of symptoms during treatment, followed by 
the reappearance of symptoms after treatment cessation. The term “recurrence” is used to 
describe both relapse and reinfection. A relapse refers to infection by the same strain of bacteria 
as the previous infection, whereas a reinfection involves colonization by a separate strain 
(Figueroa et al., 2012). It is not usually possible to clinically differentiate relapse and reinfection, 
but discernment is rarely warranted. Molecular typing of C. difficile is almost exclusively 
performed for research, although knowing the recurrence type may be helpful when treating a 
severe case. In a study of samples from ninety participants with recurrent CDAD, relapse 
(83.3%) was more common than reinfection (16.7%). All sample donors were adults, and most 
lived in the same area, which could account for the lack of reinfection diversity within the group. 
The time to relapse or reinfection is variable and, in this case, no significant difference was 
found (12.2 ± 6.4 days with relapse vs 14.7 ± 6.0 days with reinfection; P=0.18). Recurrence is 
usually seen within weeks, but may occur up to three months following the initial treatment. For 
administrative and surveillance purposes, the CDC’s Emerging Infections Program Healthcare-
Associated Infections Community Interface defines repeated CDAD episodes differently, as a 
time-based, rather than functional categorization; a duplicate is a positive specimen within two 
weeks of the last positive specimen, a recurrence is defined as a positive specimen between two 
to eight weeks of the last positive specimen, and any positive result beyond eight weeks of the 
previous positive result is considered a new case. This convenience classification was criticized 
in a surveillance study by Kamboj et al. (2011), as relapses constituted 65% of recurrences after 
eight weeks when assessed by PCR ribotyping. 
When standard antibiotics were administered, recurrence affected 20-30% of patients 
(Cornely et al., 2012). For patients with more than one recurrence, the risk of an additional 
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episode was 40-60%. As previously indicated, colonization is not protective. The implications of 
recurrence should not be understated; a Canadian study reported that 11% of patients with 
recurrent infection experienced at least one serious CDAD complication, including shock, 
colectomy, megacolon, perforation, or death within 30 days of diagnosis (Pepin et al., 2006). 
Treatment options 
Antibiotics 
Evidence suggests that the increased presence of C. difficile in the hospital, long-term 
care facilities, and the community is correlated with declining bacterial susceptibility to 
antimicrobial agents (Peláez et al., 2002). Even the gold standard antibiotics are not 
recommended for continuous use. Metronidazole, which was recommended as the first line of 
treatment for uncomplicated cases until 2018, is known to elicit neurotoxicity over time and was 
not approved by the U.S. Food and Drug Administration (FDA) for this use (Cohen et al., 2010). 
Vancomycin, which was primarily reserved for severe cases and infections that were refractory 
to treatment with metronidazole, was associated with recurrence rates as high as 50% (Louie et 
al., 2015). Ironically, new drugs and increasingly aggressive pulsed and tapered vancomycin 
protocols still are being tested for use in CDAD (McFarland et al., 2002; Nelson et al., 2017). 
Recent candidates, including fidaxomicin and cadazolid, delivered impressive results in 
preliminary clinical trials. A meta-analysis drawing from two recent clinical trials determined 
that fidaxomicin, although cost-prohibitive for many patients, was not inferior to vancomycin for 
curing CDAD, and associated with lower rates of recurrence for some C. difficile strains (Crook 
et al., 2012). It was approved by the FDA for use in CDAD patients in May 2011 (Venugopal 
and Johnson, 2012). Like fidaxomicin, cadazolid showed similar efficacy to vancomycin in 
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terms of clinical cure, but appeared more effective at preventing recurrence in a multi-center 
phase II trial (Louie et al., 2015). 
It should be noted that many investigations into novel drugs have not been worthwhile. A 
2011 systematic review declared that significant differences in efficacy were not found between 
vancomycin and several other candidate antibiotics, including metronidazole, fusidic acid, 
nitazoxanide, and rifaximin (Nelson et al., 2011). Moreover, clinical trials revealed unexpected 
safety concerns. Rifampin, when combined with metronidazole, delivered similar results to 
metronidazole alone for recurrence and time to symptom improvement. However, the trial ended 
in the death of nearly one-third of the patients in the rifampin combination group compared to 
just 5% in the metronidazole group (Lagrotteria et al., 2006). The study concluded that the cure 
rates for both treatments were unacceptably low, and that better alternatives are needed. 
Interestingly, this trial is one of the few to measure and report nonfatal adverse events, which 
occurred in approximately 40% of patients across both groups. 
The 2017 update of “Antibiotic treatment for Clostridium difficile-associated diarrhoea in 
adults” from the Cochrane Database of Systematic Reviews features the addition of three drugs 
that were missing from the 2011 version (cadazolid, LFF517, and surotomycin) and data from 
studies that continue to be plagued by small size and a high risk of bias (Nelson et al., 2017). 
LFF517 exhibited higher clinical response and recurrence rates when compared to vancomycin, 
but was not well tolerated by nearly 30% of recipients (Maxwell-Scott and Goldenberg, 2017). 
Adverse effects were also seen in nearly 30% of surotomycin recipients. A phase II non-
inferiority study showed reduced recurrence when compared to vancomycin, but was later 
discontinued after failing to meet two separate noninferiority criteria. 
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In addition to causing drug-related side effects, the use of antibiotics for CDAD may 
facilitate the transmission of drug-resistant pathogens. Both metronidazole and vancomycin have 
been shown to promote vancomycin-resistant enterococci (VRE) overgrowth (Al-Nassir et al., 
2008), and studies have identified CDAD as a risk factor for VRE colonization (Rafferty et al., 
1997; Zilberberg et al., 2014). Recently, investigators used a mathematical model to predict VRE 
prevalence after CDAD treatment, and reported that using a non-antibiotic treatment for 50% of 
CDAD cases produced a 18% relative reduction in institutional VRE (Grima et al., 2012). 
Antibiotic replacement may also temper the overall CDAD burden, and a similar model has 
estimated that a 30% reduction in broad-spectrum antibiotic use could reduce CDAD by 26% 
(Fridkin, 2014). 
In February of 2018, an updated version of “Clinical Practice Guidelines for Clostridium 
difficile” was released by the IDSA/SHEA with new treatment recommendations, including the 
use of vancomycin for initial and non-severe cases and fidaxomicin for severe and recurrent 
CDAD (McDonald et al., 2018). A weak recommendation based high quality evidence was made 
for the use of metronidazole exclusively for initial, non-severe CDAD when vancomycin and 
fidaxomicin were unavailable. Two phase three fidaxomicin trials indicated non-inferiority 
compared to vancomycin for primary cure, but reported recurrence rates between 15-20%, a 
significant reduction over vancomycin (Cornely et al., 2012; Louie et al., 2011). Despite the 
favorable secondary outcome obtained by fidaxomycin, due to the exorbitant cost of the narrow-
spectrum, minimally systemic drug, the practicality of this new recommendation remains 
questionable. The prices listed for a single course of metronidazole, vancomycin, and 
fidaxomicin were $22, $680, and $2,800, respectively (Surawicz et al., 2013). 
 Non-antibiotic alternatives 
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Several non-antibiotic therapies are currently being used for CDAD management. While 
surgical interventions are generally reserved for cases that cannot be otherwise controlled (e.g., 
sepsis, bowel perforation, toxic megacolon), new medical procedures, like fecal microbiota 
transplant (FMT), are becoming increasingly mainstream. FMT, which involves the transfer of a 
liquidized stool sample from a healthy donor into the GI tract of an ill patient, is a topic of great 
interest to the infectious disease community. Occasionally heralded as the new cure for recurrent 
CDAD, most studies, regardless of design, suggest efficacy. In a systematic review citing 36 
studies, 87% of patients experienced post-transfer diarrheal resolution (Cammarota et al., 2014). 
The included studies were small in scale, ranging from 4-77 patients, included only one 
randomized controlled trial (RCT), and featured a variety of recipient transfer sites, bacterial 
counts, and transfer volumes. A comparison of efficacy across FMT, vancomycin treatment, and 
vancomycin treatment with bowel lavage, reported significantly higher resolution of diarrhea in 
the FMT group (80%) than either the vancomycin (31%) or vancomycin and lavage (23%) 
groups (van Nood et al., 2013). The unusually low resolution rates in the control groups was 
attributed to the extreme recurrence history within the sample; 35 of the 43 study participants 
had experienced more than one recurrence, which authors explained as the reluctance of patients 
with other options to receive fecal infusion. Similarly, another study reported that only 53% of 
the patients with refractory CDAD who underwent FMT responded that it would be their first 
treatment choice if their symptoms recurred, despite a 91% cure rate (Brandt et al., 2012). 
Notably, the procedure is aesthetically unappealing, and long-term follow up and safety 
information is unavailable. In the aforementioned study, four patients developed “diseases of 
potential interest” following FMT that could not be definitively attributed to the procedure 
(Brandt et al., 2012). The primary contention with FMT is the fact that people cannot be sure of 
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what is being transferred. Variation in the intestinal microbiota has been experimentally linked to 
blood-brain barrier permeability (Braniste et al., 2014), insulin resistance (Udayappan et al., 
2014), depression (Naseribafrouei et al., 2014), and, in one unexpected and well-publicized 
human transfer, even severe weight gain (Alang and Kelly, 2015). Fecal transplants have an all-
or-nothing quality, and as with any unknown procedure, the certainty of achieving exclusively 
favorable outcomes cannot be guaranteed. In an article that echoes both fear and skepticism, 
authors wrote, “It is also worth noting that today's exceptionally healthy 25-year-old volunteer 
donor could develop major health problems in a decade” (Weil and Hohmann, 2015). 
A 2016 metagenomic analysis evaluated three different groups (experimental FMT-
transfer, sham FMT-transfer, and no intervention) three months after an FMT intervention to 
assess the fate of transferred material (Li et al., 2016). Interestingly, authors concluded that 
differences in transfer success across patients were dependent upon the compatibility of the 
donor and recipient microbiomes. In 80% of cases, the proportion of donor-specific species 
retained in recipient fecal samples was either less than or equal to the appearance of new species 
in the placebo and healthy groups. A resistance to introduced strains (39 ± 23%) and coexistence 
of donor and recipient strains (44 ± 14%) occurred. Highly variable transfer profiles were 
observed among recipients from a shared donor, and the presence of donor-specific, single-
nucleotide variants (SNV) ranged from 12.0% to 55.6%. Effective transfer and dominance vs 
rejection of donor strains were not specific to a particular species, affected by strain abundance, 
or dependent upon clinical characteristics of the patients. The identification of SNPs prior to 
transfer and use of control groups to monitor and validate results were unique aspects of this 
work. The rejection of unshared strains and a lack of uniformity among responses emphasize the 
mutualistic nature between native and novel bacteria, as well as the need for tailored treatments.   
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Future obstacles for FMT include the identification and recruitment of healthy donors, 
development of an individualized treatment and standardized protocol, and the establishment of 
consistent regulatory criteria that align with the partial FDA withdrawal of “enforcement 
discretion”. The relative success of FMT over conventional treatment implicates the microbiota 
in both disease acquisition and eradication.  
In summary, host bacteria enhance immunity and provide a physical and biochemical 
barrier against opportunistic colonization; antibiotics, administered with the intention of 
restricting or destroying pathogenic bacteria, assert bacteriostatic or bactericidal effects on the 
adjacent microbiota. Taken together, disease recurrence following antibiotic treatment and 
subsequent bacterial clearance following FMT imply that the long-term efficacy of antibiotics 
may be dependent upon the host’s ability to repopulate the GI tract. Therefore, targeted 
interventions that protect or reestablish commensal microbiota may have vast therapeutic 
implications. 
Prophylaxis 
Intestinal bacteria are vital to host health and are required for nutrient and drug 
metabolism, vitamin synthesis, immune regulation, and protection against pathogens. The 
microbiota are critical for GI maintenance and repair, and are easily supplemented by dietary 
means. The human GI tract represents over 1,000 bacterial species and approximately 95% of the 
bacterial microbiome (Lloyd-Price et al., 2016). At the individual level, bacterial structure is 
affected by genetics, environment, health, diet, age, and exposure to antimicrobial agents. 
Remarkably, seemingly innocuous foods and ingredients have been shown to favor pathogenic 
growth and disease; a recent article linked the FDA approval of the disaccharide, trehalose, as a 
food additive in the year 2000 to the rise of an epidemic C. difficile strain (Collins et al., 2018). 
32 
 
Two C. difficile strains were uniquely able to survive on low levels of environmental trehalose, 
and when mice fed a high-trehalose diet were infected with these strains, bacterial toxin 
production and mortality were greatly increased. 
An estimated 150-170 species may predominate in the human colon at any given time 
yet, with few exceptions, commensal bacteria exhibit remarkable stability throughout the lifetime 
of their host (The Human Microbiome Consortium, 2012). The intestinal dysbiosis and reduction 
in bacterial diversity observed among CDAD patients suggests that restoration of the appropriate 
microbiota could yield favorable outcomes (Chang et al., 2008).  
Probiotics and prebiotics are known to amplify non-pathogenic bacteria, promote 
microbial diversity, restrict pathogen adherence, and have been used anecdotally and 
experimentally for patients with various bowel disorders to reduce clinical symptoms and 
maintain remission. The ingestion of probiotics, or live microorganisms used to exert changes on 
the microbiome, has shown potential in patients with CDAD. However, premature degradation in 
the upper GI tract can be problematic, and caution is advised for use in critically ill or 
immunocompromised patients. Conversely, prebiotics have not been investigated as thoroughly, 
but may offer greater stability with lower risk and cost. 
Probiotics 
Research showing the effect of probiotics on C. difficile-related parameters has advanced 
significantly within the last decade. A 2008 Cochrane review of 336 patients across four studies 
determined that there was insufficient evidence to recommend probiotics as an adjunct or 
individual treatment for C. difficile (Pillai and Nelson, 2008). Among the low number of 
qualifying studies, a randomized placebo-controlled trial measuring outcomes in CDAD patients 
treated with antibiotics and either a placebo or Saccharomyces boulardii, showed potential for 
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probiotic therapy. The addition of S. boulardii significantly reduced recurrence in patients with 
recurrent CDAD, but did not prevent a first recurrence for patients with an initial CDAD episode 
(McFarland et al., 1994). 
Five years later, an updated Cochrane review, which cited 31 studies with 4,492 total 
participants, concluded that moderate quality evidence indicated probiotic use for the prevention 
of C. difficile diarrhea (Goldenberg et al., 2013). The use of probiotics reduced C. difficile 
diarrhea by 64%, and similar results were reported in trials with either adults or children, low or 
high doses of probiotics, and across different probiotic species. A 20% reduction in risk of 
adverse events was calculated from 26 studies with 3,964 participants. Conversely, reports from 
13 trials with 961 patients showed that the incidence of infection was not different between 
probiotic and control groups.  
Similarly, a 2012 systematic review and meta-analysis of 20 trials with 3,818 patients 
revealed a 66% decrease in C. difficile diarrhea for patients receiving probiotics (RR 0.34; 95% 
CI 0.24 to 0.49) and studies administering multiple species showed larger effects (RR 0.25; 95% 
CI, 0.15 to 0.41) than those using one species (RR 0.50; 95% CI, 0.29 to 0.84) (Johnston et al., 
2012). A reduction in adverse events was noted for patients in the probiotic group (9.3% with 
probiotics vs 12.6% of control; RR 0.82; 95% CI, 0.65 to 1.05). A 2016 systematic review 
(which included many of the same studies as the other reviews) with 7,957 patients across 26 
RCTs also concluded that fewer patients treated with probiotics developed CDAD (1.5% 
probiotics vs 3.8% control, P<0.001), and added that Lactobacillus (RR 0.36, 95% CI 0.23 to 
0.59; P<0.001), Saccharomyces (RR 0.42, 95% CI 0.212 to 0.80; P=0.008), and a mixture of 
probiotics (RR 0.42, 95% CI 0.26–0.66; P<0.001) all specifically reduced CDAD risk (Lau and 
Chamberlain, 2016). Neither study reported infection rates. 
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Perhaps the most compelling primary evidence for the use of probiotics for CDAD 
prevention comes from a 2007 randomized placebo-controlled trial of 135 patients receiving 
antibiotics (Hickson et al., 2007). Fewer patients in the probiotic group developed diarrhea than 
in the control group (12% with probiotics vs 34% with placebo; P=0.007), and none of the 
patients treated with probiotics developed CDAD (0% with probiotics vs 17% with placebo; 
P=0.001). Realistically, results may not be generalizable, as among the 1,760 eligible patients, 
148 refused to participate in the trial, 1,167 were rejected for reasons involving confounding 
sources of diarrhea, recent antibiotic use, and informed consent, and another 310 were rejected 
for safety reasons, such as severe illness and immunosuppression; of the 135 patients 
participating in the trial, 22 (16%) were lost to follow-up. Unfortunately, serious limitations were 
present in many of the C. difficile and probiotic studies, including, but not limited to, non-
generalizable or missing data, poor selection criteria, significant patient loss, and small sample 
size.  
Probiotics are generally considered safe by the public (and many have obtained Generally 
Recognized as Safe, or GRAS, status), yet some trials have reported safety concerns involving 
their use in immunocompromised or severely ill populations (Besselink et al., 2008; Enache-
Angoulvant and Hennequin, 2005). However, the estimated risk for developing infection from S. 
boulardii or lactobacillus species is one in 5.6 million users and less than one in one million 
users, respectively (Karpa, 2007). In conclusion, the literature is best summarized in the CDAD 
recommendations from the American College of Gastroenterology:  
There is limited evidence for the use of adjunct probiotics to decrease recurrences in 
patients with RCDI… Although there is moderate evidence that two probiotics (L. 
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rhamnosus GG and S. boulardii) decrease the incidence of antibiotic associated diarrhea, 
there is insufficient evidence that probiotics prevent CDI (Surawicz et al., 2013). 
Synbiotics 
A synbiotic is a combination of a probiotic and a prebiotic. The prebiotic is believed to 
enhance the survival of the probiotic and promote intestinal colonization. A study measuring 
symptomology and colonization of CDAD in a mouse model assigned animals to either a 
prebiotic, probiotic, or synbiotic (Kondepudi et al., 2014). Selected probiotics included L. 
plantarum F44, L. paracasei F8, B. breve 46, and B. lactis 8:8. Galactooligosaccharide (GOS), 
isomaltooligosaccharide (IMOS), and resistant starch (RS) were administered as prebiotics. All 
animals were given antibiotics, and after two days, half of the control mice became moribund 
and were sacrificed. No CDAD toxins were found in the synbiotic, probiotic, or prebiotic mice at 
the end of the experiment, whereas control mice expressed toxin throughout the study. 
Histopathology showed that all control mice, but only 17% of all treated mice exhibited cecal 
inflammation. Animals in the synbiotic group had higher bacterial counts than animals in the 
other groups, but all treatments provided protection against CDAD. 
In a non-controlled retrospective analysis of 120 nursing home residents using antibiotics, 
chewable synbiotic tablets containing S. boulardii (7.5 billion cfu), B. coagulans (1 billion cfu), 
and 500 mg fructooligosaccharide (FOS) were provided twice a day beginning shortly after the 
onset of antibiotic treatment, and continuing for two weeks after antibiotic cessation (Spielholz, 
2011). Antibiotic-associated diarrhea (AAD) did not occur in 95% of residents treated with 
antibiotics and synbiotics. Two residents were diagnosed with C. difficile infection, but only one 
was credited with having CDAD (tested positive for C. difficile and presented with symptoms of 
AAD). The method of C. difficile detection was not specified. No adverse effects were reported, 
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and the synbiotic was well tolerated overall, as mild gastrointestinal side effects were observed 
in less than 6% of residents. Inconsistent data and subject reporting, including unclear handling 
of non-compliant residents and drop-outs, as well as the removal of subjects for incomplete data 
sets, hindered the interpretation of evidence.  
The uncontrolled design employed in this study is unfavorable from a research 
perspective, as it prevents the generalizability of data and cannot confirm efficacy without a 
proper control group for comparison. However, results indicate that the synbiotic is unlikely to 
cause significant harm, and the author may be able to use the unilateral intervention to help 
inform and improve in-house policies. 
Synbiotics are an appealing option for supplementation, as they appear to combine the 
best of both probiotics and prebiotics. However, studies have reported that this assumption may 
not be accurate, and that the addition of certain probiotics can negate any benefit afforded by the 
prebiotic (Barnes et al., 2012; Madeo and Whitlick, 1999). Therefore, matching the appropriate 
type and dosage of the prebiotic and probiotic is imperative. 
Prebiotics 
Prebiotics are non-digestible substances that are selectively fermented by colonic 
microbiota. The most thoroughly studied prebiotics are fructoologosaccharides (FOS) and inulin. 
Other common types include galactooligosaccharides (GOS), xylooligosaccharides (XOS), and 
resistant starch (RS). Though not studied as extensively as probiotics, there is evidence, 
especially from in vitro and animal studies, that prebiotics could impair C. difficile colonization, 
growth, or virulence (Ambalam et al., 2015). Their ease of production and delivery, survival 
through inhospitable parts of the GI tract, and ability to maintain colonization resistance make 
prebiotic supplementation a promising avenue for future research.  
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The fermentation of dietary prebiotics yields several physiologically relevant products. 
Among them, short-chain fatty acids (SCFA) and lactic acid serve to decrease luminal pH, 
thereby providing an inhospitable colonic environment for exogenous microbe colonization. The 
primary SCFA include acetate, propionate, and butyrate. In particular, butyrate provides 
approximately 70% of the energy for the colonic mucosa, and mediates the immune response by 
inducing growth arrest and apoptosis (Carding et al., 2015). High SCFA concentration and low 
pH have been shown to regulate C. difficile in vitro (May et al., 1994).  
Prebiotics are thought to exert protective action by acting as a substrate for either one or a 
limited number of beneficial bacteria, especially bifidobacteria and lactobacilli. In vitro studies 
have detailed the ability of bifidobacteria, lactobacilli, and bacteroides strains, isolated from 
stool samples of healthy volunteers, to prevent C. difficile growth (Rolfe et al., 1981), and 
bifidobacteria supernatants have proven effective at inhibiting C. difficile growth and preventing 
adherence to enterocytes (Trejo et al., 2006). A non-interventional clinical study concluded that 
the presence of indigenous lactobacilli was protective against CDAD development after 
measuring higher lactobacillus counts from fecal samples taken from C. difficile negative 
patients than C. difficile positive patients (Naaber et al., 1997); this may provide a direct 
connection between known prebiotic function and freedom from pathological infection and 
CDAD.  
An in vitro study with human fecal samples from three healthy volunteers examined the 
results of clindamycin or vehicle treatment with supplementation with one of three experimental 
non-digestible oligosaccharide (NDO) preparations—galactooligosaccharide (GOS), 
fructooligosaccharides (FOS), or inulin (Hopkins and Macfarlane, 2003). Samples were tested at 
five time points over 48 hours. Fecal samples unaltered by clindamycin showed C. difficile 
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growth inhibition with NDO (P<0.05), which was paralleled by increased bifidobacteria counts 
(P<0.01). The reverse was seen in the clindamycin-treated groups, as NDO had no suppressive 
effect on C. difficile samples, which mostly contained slightly more bacteria than their respective 
controls. However, bifidobacteria concentrations were decreased by clindamycin, and further by 
NDO (P<0.05). NDO addition increased SCFA by 12 hours, and major fermentation products 
were acetate, propionate, and butyrate. As expected, addition of clindamycin to the samples 
decreased SCFA formation. The only toxin discovery was in the antibiotic and FOS group at 24 
hours. In summary, NDO stimulated bifidobacteria growth and reduced C. difficile. Upon the 
addition of clindamycin, bifidobacteria were severely reduced, especially when incubated with 
NDO. Without antibiotic intervention, NDO improved colonization resistance, but the effects 
were not attributable to the action of bifidobacteria.  
Several animal studies have examined CDAD-related outcomes after prebiotic feeding 
with FOS (Gaskins et al., 1996; Wolf et al., 1997). In a study measuring C. difficile diarrhea and 
toxin A production, mice were divided into control and antibiotic groups, fed either a control diet 
or the same diet supplemented with FOS, and all inoculated with C. difficile (Gaskins et al., 
1996). After prebiotic feeding, toxin A titers were elevated only in the antibiotic-treated group 
with the control diet; both the antibiotic and control animals fed FOS-supplemented diets had 
normal toxin A titer. No difference in diarrheal severity was noted between the groups for 
animals receiving antibiotics, but non-antibiotic animals given the FOS-supplemented diet had 
lower diarrheal severity than animals consuming the control diet. Authors suggested that the FOS 
may directly bind toxins, leading to reduced toxin A titers, but that the protective effects of FOS 
may be dependent or increased by microbiota.  
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Another animal study of FOS supplementation in a CDAD model revealed that hamsters 
given FOS-supplemented drinking water had an increased mean survival time after inoculation 
with C. difficile (15 days with FOS vs 13.5 days with control; P<0.001) (Wolf et al., 1997). A 
subsequent 2x2x2 factorial hamster experiment provided either an antibiotic or a non-antibiotic 
control to animals receiving FOS-supplemented or control water, with or without inoculation. 
Results were similar to the previously mentioned mouse study, and showed that FOS 
supplementation improved outcomes for inoculated animals that did not receive antibiotics (14.5 
days with FOS vs 13 days with control; P=0.07), but did not affect outcomes for inoculated 
animals that received antibiotics (19 days with FOS vs 20 days with control; P=0.7); like the in 
vitro Hopkins study, these data support the hypothesis that protection against C. difficile by FOS 
is dependent upon the existing microbiota. FOS increased survival of uninoculated animals that 
received antibiotics (19 days with FOS vs 17.5 days with control; P=0.02), and for uninoculated 
control animals (16.5 days with FOS vs 13.5 days with control; P=0.003). An interaction 
between antibiotics and inoculation was indicated. Hamsters that received antibiotics lived 
longer than those that were not treated, and in both hamster experiments, when all animals were 
pooled, FOS increased survival time compared to controls.  
Interventional studies with prebiotics in human subjects 
Although the use of prebiotics in clinical research is common, the majority of the existing 
evidence involves the supplementation of milk formula in newborns and infants. Unfortunately, 
since the efficacy of prebiotic supplementation is dependent upon the preexisting microbiota, 
insights gained by these studies are not compatible with the expectations of adult 
supplementation. Up to 70% of newborns and infants are colonized by C. difficile, but CDAD is 
rarely acquired (Ghose, 2013). It has been proposed that the lack of symptoms in colonized 
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infants is either due to increased protection afforded by Bifidobacteria (which represents 60-70% 
of the infant microbiome) (Arboleya et al., 2016), neutralization of the toxin by secretory IgA 
and oligosaccharides from breast milk, or a lack of functional C. difficile toxin receptor within 
the infant GI tract (Jangi and Lamont, 2010). While rare, CDAD can manifest in children 
(Schutze and Willoughby, 2013). A multicenter trial investigated the ability of inulin and FOS to 
prevent AAD and CDAD in children ranging in age from six months to 11 years (Szajewska et 
al., 2012). Participants received antibiotic treatment concurrently with either five grams of inulin 
and FOS or a maltodextrin placebo. Ninety-two children completed the study, no adverse effects 
were reported, and the prebiotic mixture was well tolerated. No significant differences were 
observed between the prebiotic and placebo groups in terms of the quantity of participants with 
diarrhea (6.7% with prebiotic vs 10.6% with placebo; RR 0.63; 95% CI 0.16 to 2.5), and the 
proportions of participants with AAD, both with and without C. difficile toxin (6.7% with 
prebiotic vs 8.5% with placebo; RR 0.78; 95% CI 0.19 to 3.3). This study showed no evidence 
for the use of inulin and FOS in the prevention of AAD, but the selection criteria were stringent, 
the number of participants with diarrhea was low (only seven participants between both groups), 
and the study was underpowered. 
Publications involving prebiotic administration (either individually or with a probiotic) 
for prevention or treatment of C. difficile in adult human populations are limited to four full-
length articles (Lewis et al., 2005a; Lewis et al., 2005b; Madeo and Whitlick, 1999; Spielholz, 
2011) and two conference abstracts (Licht and Maltz, 2012; Rhim, 2008); results from the 
applicable interventions were analyzed in a systematic review, but the details of the individual 




 One of the conference abstracts considered for review was ultimately excluded due to the 
presence of a prognostic imbalance that confounded the study objectives (Rhim, 2008). A 
retrospective, case-control study of hospitalized patients with cirrhosis planned to use records 
obtained between January 2001 and March 2006 to confirm that lactulose ingestion could 
prevent C. difficile infection (CDI). A large sampling pool of 4,566 patients with decompensated 
cirrhosis were considered for the analysis. Exclusion criteria included the presence of diarrhea on 
admission and a recent positive C. difficile toxin assay. Within the cohort, cases of CDI were 
identified. CDI negative controls were randomly selected, but matched by age, sex, hospital 
location, and admission period. 35 CDI patients and 75 controls were selected and Chi-squared, 
t-tests, and conditional logistic regression were used for analysis. Hepatic encephalopathy (HE) 
was not selected as a covariate for the model, as it is highly related to lactulose exposure (the 
author introduces lactulose as a treatment for both HE and constipation). Results of their analysis 
suggested that lactulose decreased CDI, but needed to be confirmed in other populations. 
Madeo, Whitlick, and Martin, 1999 
The earliest preventive clinical CDAD and prebiotic study was an RCT that examined the 
ability of either a prebiotic (9.1 g FOS) or synbiotic (8.5 g FOS+ L. acidophilus and B. bifidum) 
to prevent AAD (including CDAD) in elderly hospital patients receiving oral antibiotics (Madeo 
and Whitlick, 1999). Sixety-six patients were blinded and randomized to receive either prebiotic, 
synbiotic, or control (9.1 g maltodextrin) granules once a day at the onset of antibiotic treatment. 
The intervention lasted for 15 days and patients were monitored for up to 10 additional days. 
Bowel action, frequency, and consistency were recorded by ward staff, and any diarrheal 
samples were examined for pathogens and C. difficile toxin. Patients who were discharged before 
the end of the study were sent home with granules and follow-up was completed by 
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telephone. Additionally, their physicians were contacted and asked to send stool samples if they 
developed diarrhea within two weeks. 
AAD was only reported among six people in the study; four (13.3%) were from the 
synbiotic group and two (11.1%) were from the placebo group. No one in the prebiotic group 
acquired AAD, and differences were not significant. Despite mention of it in the study design, 
the results either failed to find a causative pathogen or C. difficile toxin, or neglected to report 
their results. Authors did not comment on adverse events. 
Licht and Maltz, 2012 
In a 190 patient retrospective case-control study, unspecified doses of antibiotics were 
administered with or without the addition of lactulose to determine whether lactulose was 
effective in preventing “C. diff” (Licht and Maltz, 2012). The duration of treatment was not 
specified, but fewer patients in the lactulose group developed “C. diff” (2.3% vs 9.7%; OR 0.22; 
P=0.05). Results were presented vaguely as an abstract, and adverse events were not reported. 
Interestingly, there was no mention of diarrhea beyond the title or what the lactulose was 
prescribed for, only that it is “commonly utilized in the management of constipation and hepatic 
encephalopathy”. Furthermore, by excluding retrospective records of patients who received 
metronidazole or vancomycin (the primary treatments for CDAD), the authors likely removed 
many patients who were diagnosed and treated for the disease of interest during their hospital 
stay. Lastly, it seems unlikely that admissions to the medicine and surgery services of a large 
academic medical center would enroll only 87 subjects over the course of a year. 
Lewis, Burmeister, and Brazier, 2005 
The remaining two human CDAD studies were RCTs using high-dose oligofructose 
powder (12 g/day) and antibiotics. The first of the studies measured relapse of diarrhea following 
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diarrheal cessation, treatment failure, and C. difficile toxin in 142 consecutive inpatients with 
CDAD (Lewis et al., 2005a). Of 527 subjects identified as C. difficile toxin-positive, 142 
participated in the study (93 declined, 186 could not provide consent, 51 were excluded due to 
diabetes, and 55 were excluded due to immunosuppression or GI disease), and five patients 
discontinued the powders after a few days (one oligofructose, four placebo), as they disliked the 
taste. The prebiotic powder or sucrose was given along with antibiotics beginning at the time of 
diagnosis, and ending 30 days after the cessation of diarrhea. Patients were assessed after 30 
days (with termination of the prebiotic or placebo) and followed up with 30 days later.  
Oligofructose supplementation reduced relapse (8.3% vs 34.3%; OR 0.17; P=0.0004), but 
not treatment failure (6.9% oligofructose vs 4.3% control; OR 1.67; P=0.5) or asymptomatic 
carriage at 30 days (43.1% vs 58.6%; OR 0.53; P=0.07) or 60 days (34.7% vs 48.6%; OR 0.6; 
P=0.1). Nineteen (13%) deaths were reported, but fatality rates for relapsing patients did not 
differ between groups (17% vs, 8.3%, OR 2.2, NNTH=12; P=0.6). C. difficile was not provided 
as a primary cause of death in any case. 
The authors stated an intention-to-treat (ITT) analysis, yet evaluation of the results from 
terminal patients suggested classification by their last observation carried forward (although this 
is not discussed in the text). It is unclear whether the five patients who refused treatment after 
several days were dismissed from the study or included within the 142-patient data set, and data 
reporting among tables appeared to be inconsistent. C. difficile was not remeasured/confirmed in 
patient samples upon diarrhea recurrence, but this represents more of a methodological issue than 
author bias. 
Lewis, Burmeister, Cohen, Brazier, and Awasthi, 2005 
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The other study published by the same primary author within the same year examined the 
efficacy of high-dose oligofructose (12 g/d) in preventing multiple types of AAD, including 
CDAD (Lewis et al., 2005b).  Unlike the relapse study, results of this trial were not significant. A 
total of 116 patients (27%) experienced diarrhea, with similar results between groups; diarrhea 
was reported in 56/215 (26%) and 60/220 (27%) patients who received oligofructose and 
placebo, respectively (OR=1.0, NNTB=117, p=0.8). When stratified by severity, 36 patients in 
the prebiotic group presented with significant diarrhea, and another 20 patients experienced non-
significant diarrhea vs 37 significant and 23 non-significant cases in the placebo group. Severe 
adverse events, including death among patients with significant CDAD, occurred in 2/19 
(10.5%) patients in the oligofructose group. Exclusion of 15 patients from analysis (eight for GI 
bleeds and seven before treatment was provided) contradicted the stated ITT analysis. 
The current evidence regarding the use of prebiotics for CDAD is extremely diverse, but 
most of the studies indicate that prebiotic administration improved outcomes within their 
respective study population. In order to fairly assess the available research, a systematic review 
was conducted and presented in the next chapter of this thesis. The initial hypothesis was, that 
with appropriate prebiotic selection, dosage, and treatment duration, as well as careful selection 
of the precipitating antibiotic (for high-risk patients), prebiotic supplementation may represent a 
safe and effective method of preventing infection in humans, and may reduce the need for further 
antibiotic use and microbial depletion. However, after summarizing research and pooling 
outcomes, where appropriate, the results of the systematic review were unable to either 
corroborate or disprove the hypothesis due to scarce, low-quality, and heterogeneous evidence. 
Additionally, two separate retrospective chart reviews were conducted using inpatient 
records from Carle Foundation Hospital (CFH) to identify and validate specific risk factors for 
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CDAD and determine whether malnutrition was related to CDAD acquisition. The identification 
of at-risk patients is critical, but the lack of consensus surrounding many of the published risk 
factors makes generalization problematic. Historically, the precipitous rise in CDAD prevalence 
following outbreaks with epidemic strains illustrates the fact that infectivity and toxigenic 
potential vary greatly among different types of C. difficile, and contribute to regional, national, 
and global infection patterns. Risk may also be modified by regulated hospital practices, such as 
infectious disease surveillance, antibiotic stewardship programs, proper sanitation, and 
conscientious patient care. 
The retrospective chart reviews represent data from two separate years, and will comprise 
the fourth and fifth chapters of this thesis. The initial review was conducted using data from 
2014, and was separated into a preliminary and a primary study. The second chart review, 
conducted using 2016 data, was intended to validate the 2014 review and surveil regional 
CDAD, malnutrition, and mortality rates over time. The overarching goal of this research was to 
combine the knowledge obtained in the systematic review and both chart reviews into a clinical 
study to be conducted at CFH. The retrospective chart reviews were specifically designed to help 
identify which patients would benefit most from a nutrition intervention and facilitate the rapid 
and reliable recruitment of high risk patients upon admission, prior to potential C. difficile 
exposure during the hospital stay.  
In summary, the most practical way to mitigate prospective disease burden is to protect 
people at risk. Prophylactic therapies may benefit the host by resisting pathogenic colonization, 
neutralizing enterotoxins and cytotoxins, strengthening an immune response, and either 
protecting or restoring endogenous colonic microbiota. The ability to evade opportunistic 
infection will lessen the individual disease burden and prevent transmission to others via passage 
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of spores. Hospital implementation of such a strategy could inhibit the spread of CDAD within 






















CHAPTER 3: USE OF PREBIOTICS FOR PREVENTION AND REDUCTION OF 





The present systematic review collates research on the use of prebiotics for the 
prevention of Clostridium difficile-associated disease (CDAD). The literature search examined 
studies published up until May 2016 using the following search terms: Clostridium difficile 
infection, Clostridium difficile disease, diarrhea, prebiotics, fructans, lactulose, galacto-
oligosacharides, and inulin. Five studies fullfilled the inclusion criteria, and evaluated prebiotic 
supplementation in adult patients at risk for CDAD. Prebiotics were administered during and 
after antibiotic treatment independently in four studies, and in conjunction with a probiotic 
(synbiotic) in two studies; pooled results examined prebiotic interventions either with or without 
the accompanying probiotic. Although prebiotics may safely and effectively decrease the 
incidence of CDAD among at-risk adults, insufficient evidence prevents the accurate assessment 
of clinical benefit. 




Clostridium difficile–associated disease (CDAD) most commonly occurs in elderly 
hospitalized patients with a recent history of antibiotic use, and is a significant cause of 
morbidity and mortality among hospitalized adults. CDAD is an opportunistic bacterial infection 
that requires the displacement of the normal colonic microbiota with subsequent pathogen 
ingestion, germination, colonization, and proliferation. In addition to recent hospitalization and 
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antibiotic use, risk factors for CDAD include advanced age, admission from a long-term care 
facility, length of hospital stay, previous diarrhea or CDAD, malnutrition, polypharmacy, and 
compromised immunity (Bignardi, 1998; Cooper et al., 2013; Klingler et al., 2000; Monge et al., 
2011; Wong et al., 2009). Treatment is complicated by a high recurrence rate, caused by either 
reinfection or recolonization with residual bacterial spores (Figueroa et al., 2012; Wilcox et al., 
1998). Recurrence and treatment failure are common with the existing antibiotic regimens and 
have been reported in 22% and 21% of patients, respectively (Vardakas et al., 2012). The 
precipitating role of antibiotic administration in CDAD development and the recent success of 
fecal microbiota transplants for animal and human subjects with recurrent CDAD reflect the 
importance of microbiome dysregulation in disease establishment, as well as the potential for 
symptom abatement through the restoration of normal gastrointestinal (GI) microbiota. For 
patients with CDAD, long term cure relies not only upon pathogen elimination, but the 
regeneration of colonization resistance. 
The highly resilient and transmissible nature of Clostridium difficile (C. difficile) 
emphasizes the need for future therapies that focus on the prevention of CDAD, rather than the 
management of primary, recurrent, and treatment-resistant disease. Any therapy that aids the 
reinforcement and rapid recovery of endogenous GI defenses, primarily the microbiota, may 
prevent pathogenic colonization entirely, and thereby reduce CDAD-related morbidity, mortality, 
and costs, and create safer healthcare environments. 
CDAD emerged as an international threat in the early 2000’s when hypervirulent strains, 
most notably BI/NAP1/027, were detected throughout the United States, Canada, and Europe. 
Expectedly, data from this period reflect escalated incidence, severity, and mortality (See et al., 
2014). In the United States, the rate of CDAD hospitalization per 1,000 discharged adults 
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increased from 5.6 in 2001 to 12.7 in 2011 (Steiner et al., 2014) and was projected to reach 14.2 
in 2013; an estimate released by the CDC corroborated this timeline (CDC, 2016), yet the 
Healthcare Cost and Utilization Project (HCUP) did not confirm this peak prevalence until 2015 
(HCUP, 2018). According to the CDC, in 2015, patients experienced an unprecedented 14.9 
CDAD cases per 1,000 patient discharges (CDC, 2017).  
Infection rates in Canada increased modestly from 4.7 to 5.4 nosocomial CDAD cases 
per 1,000 admissions from 2007 to 2011, but decreased to 3.6 in 2014. A recent survey of 95 
Quebec hospitals estimated a nosocomial CDAD incidence of 6.8 per 10,000 patient-days from 
April 2014 to March 2015 (Garenc et al., 2016), whereas The European Centre for Disease 
Prevention and Control (ECDPC) reported that the United Kingdom, Finland, and Poland each 
described an incidence of greater than 10 per 10,000 patient-days (ECDPC, 2015). While CDAD 
rates appear lower in certain parts of Europe, Latin America, Asia, and Africa, it is unclear 
whether these estimates accurately reflect overall disease prevalence or regional variations in 
clinical detection and surveillance practices. 
CDAD represents a significant social and economic burden. In 2009 alone, the U.S. and 
Canada spent $8.2 billion (Lucado et al., 2012) and over $281 million, respectively, on CDAD 
treatment (Levy, 2013). In Europe, the annual cost of CDAD has been estimated at €3000 
million and is expected to double over the next four decades due to a growing elderly population 
(Kuijper et al., 2006). Remarkably, the extensive utilization of financial, medical, and personal 
resources has not fostered overtly positive outcomes; between 2000 and 2007, a U.S. study 
reported a five-fold elevation in mortality attributable to CDAD, from 2,675 to 14,368 deaths per 
year (Hall et al., 2012). Approximately 10% of CDAD cases prove fatal within 30 days of 
diagnosis (Lessa et al., 2015). 
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Clinical practice guidelines developed by the Society for Healthcare Epidemiology of 
America (SHEA) and the Infectious Diseases Society of America (IDSA) recommend 
metronidazole for standard infections and vancomycin for severe or recurrent cases (Cohen et al., 
2010). Experimental alternatives, including the newer antibiotics, fidaxomicin and rifaximin, as 
well as intravenous immunoglobulin therapy, fecal transplantation, and the administration of 
probiotics and prebiotics are under investigation (Brunser et al., 2006; Cocanour, 2011; Surawicz 
and Alexander, 2011). With growing concerns about antibiotic resistance and the inability of 
antibiotics to prevent recurrent infections, therapies that target the microbiome are becoming 
increasingly salient options. Prebiotics are selectively fermented ingredients that promote 
changes in the composition and activity of the gastrointestinal microbiota to confer benefits upon 
the host (Roberfroid, 2007). Examples include fructans, such as inulin, oligosaccharides, and 
fructooligosaccharides (FOS), as well as galactooligosacharides (GOS), and lactulose (Gibson et 
al., 2004). GOS is naturally found in human and cow milk (Tuohy et al., 2005), lactulose is a 
synthetic sugar produced by the alkaline isomerization of lactose (Licht et al., 2012), short-chain 
FOS (scFOS) is a synthetic food additive derived from sucrose, and fructans are found in a 
variety of vegetables including onions, chicory root, artichokes, and agave (Mancilla-Margalli 
and Lopez, 2006). The site and extent of intestinal fructan fermentation by luminal bacteria are 
affected by its molecular structure and degree of polymerization (DP), and short-chain and long-
chain fructans are fermented in the proximal colon (Hegazi, 2013). An expanded definition of 
prebiotics was released in 2017 by the International Scientific Association for Probiotics and 
Prebiotics (ISAPP) that extends to non-carbohydrate substances and non-food categories; 
fermentation selectivity and health benefits in the selected host remain vital to classification 
(Gibson et al., 2017).    
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Prebiotics are known to confer health benefits through several complementary 
mechanisms. Within the colon, prebiotic fermentation yields short-chain fatty acids (SCFA), 
primarily acetate, propionate, and butyrate. SCFA production decreases luminal pH to inhibit the 
adherence and proliferation of pathogens (Hegazi, 2013; Ríos-Covián et al., 2016), while 
butyrate specifically serves as the primary energy source for colonocytes and affects both 
intestinal and systemic processes (Canani et al., 2011). In addition to preventing pathogenic 
colonization, prebiotics selectively enhance the growth or activity of beneficial microbiota, 
regulate host immunity, improve mineral bioavailability, and reinforce intestinal integrity 
(Khailova et al., 2009; Searle et al., 2010). The protective effects of prebiotics against CDAD 
have been demonstrated with animal and in vitro studies (Hegazi, 2013; Wolf et al., 1997). 
Investigation into the therapeutic potential of prebiotics is further warranted by cost and 
safety data. Prebiotics are generally well-tolerated in both healthy and critically ill populations 
(Manzanares and Hardy, 2008). Furthermore, their presence in naturally occuring edible plants, 
widespread availability as dietary supplements, and integration into popular comestibles attests 
to their biochemical stability and marketability. Although the evidence is limited, prebiotics may 
be a practical, affordable, and effective option for the prevention and treatment of CDAD. The 
objective of this systematic review was to assess the efficacy of prebiotic therapy for the 




This study was conducted according to the procedures outlined by the Cochrane 
Collaboration for systematic reviews (Higgins and Green, 2011). A standard protocol for study 
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identification, inclusion, and data abstraction was developed and followed after establishment of 
the following study (Population, Intervention, Comparison, and Outcome [PICO]) question: 
“Can prebiotic consumption prevent or reduce the prevalence of CDAD in adults receiving 
antibiotic treatment?” 
Multiple electronic databases, including Cochrane Central Library, PubMed/Medline, and 
Embase, were searched through May 2016 using the following terms, alone or in combination: 
Clostridium difficile infection, Clostridium difficile, diarrhea, prebiotics, fructans, lactulose, 
fructoologosaccharides, galactooligosaccharides, and inulin. The reference lists of review articles 
were reviewed to find additional articles not identified in the electronic database. Results were 
restricted to English, French, and Spanish language studies. 
Inclusion and exclusion criteria 
Studies that registered adult CDAD and administerd prebiotic therapies either alone or in 
combination with another treatment were eligible for inclusion. Adults were defined as 
individuals aged 18 years and older. Due to the fact that symptoms rarely occur without 
microbiota dispacement, it was critical to assess adults who had recently undergone antibiotic 
treatment, as it confers susceptibility to CDAD.  
The primary outcome of interest was the prevalence of CDAD following prebiotic 
therapy. The diagnosis was confirmed by the presence of appropriate symptomology and 
coinciding evidence of C. difficile colonization in order to avoid the inclusion of unrelated GI 
illnesses and asymptomatic carriers. Reasons for exclusion included duplicate data, review 
articles, analysis from pediatric patients, and research protocols not associated with CDAD. 
Inclusion criteria were evaluated by three independent reviewers. 
Study selection  
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Articles identified in the literature search were examined by two reviewers. After 
removal of duplicate titles and abstracts, the remaining articles were screened. Full text articles 
that met inclusion criteria were retained for data analysis. Articles that did not meet inclusion 
criteria were excluded, and disagreements were resolved by a third reviewer. 
Data extraction 
A data extraction form was developed and piloted jointly by the authors, after which data 
extraction was performed by two reviewers; disagreements were resolved by a third reviewer. 
Information regarding participants, study design, interventions, outcome measures, potential 
bias, limitations, and study quality was extracted.  
Assessment of bias and quality 
Two independent reviewers evaluated the studies for methodological quality, including 
multiple domains of selection, performance, detection, attrition, reporting, and other biases. If a 
risk of bias was unclear, attempts were made to clarify by contacting the senior study authors. 
Discrepancies in trial bias assessments between reviewers were resolved by consensus or third-
party intervention. Information was summarized using RevMan software (version 5.3, Cochrane 
Collaboration). 
Statistical analysis 
Summary statistics, including therapeutic gain, (prebiotic event rate - placebo event rate), 
number needed to treat for an additional beneficial outcome (NNTB; NNTB = 1/[proportion 
benefiting for experimental intervention - proportion benefiting for control intervention]), 
number needed to treat for an additional harmful outcome (NNTH; NNTH = 1/[proportion 
benefiting for experimental intervention - proportion benefiting for control intervention), and 
odds ratio (OR; OR = [number of prebiotic-treated subjects experiencing event/number of event-
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free prebiotic treated subjects]/[number of placebo-treated subjects experiencing event/number 
of event-free placebo-treated subjects]) were calculated as described by the Cochrane 
Collaboration in order to provide safety and efficacy comparisons between prebiotic and placebo 
groups. A meta-analysis was performed on pooled CDAD prevalence data, and heterogeneity 
among studies was calculated using the I2 test. 
RESULTS 
Included studies 
A total of 2,716 citations were identified, and 2,088 unique results remained after 
removal of duplicates. Analysis of titles and abstracts yielded 22 studies for full review. Five 
studies, including four full-text manuscripts and one conference abstract, met inclusion criteria 
(Figure 3.1). Three of the studies exclusively reported prebiotic administration (Lewis et al., 
2005a; Lewis et al., 2005b; Licht and Maltz, 2012), one study included both a prebiotic and a 
synbiotic intervention (Madeo and Whitlick, 1999), and one study examined synbiotic 
intervention only (Spielholz, 2011). 
Study and patient characteristics 
The study durations, populations, and outcomes of interest from the included studies are 
represented in Table 3.1. The study designs included three randomized, controlled trials (RCTs) 
(Lewis et al., 2005a; Lewis et al., 2005b; Madeo and Whitlick, 1999), one uncontrolled trial 
(Spielholz, 2011), and one retrospective cohort study (Licht and Maltz, 2012). A total of 953 
patients were included in the five studies. Patients were predominantly elderly, and except the 
control group selected by Licht and Maltz (2012), all groups recorded a mean age greater than 65 
years. The gender distribution across groups was fairly equal, although three studies (Lewis et 
al., 2005a; Madeo and Whitlick, 1999; Spielholz, 2011) included more female patients than male 
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patients in all groups, and two studies (Lewis et al., 2005b; Licht and Maltz, 2012) included 
more females in the control group than the treatment group. All patients included in the five 
studies were prescribed an antibiotic either prior to or at the onset of prebiotic therapy. 
 Several variables, including the type of prebiotic being assessed, product dose, 
administration frequency, and method of delivery differed among the studies. The abstract did 
not report most of these items, and emailed requests for further information were not returned 
(Licht and Maltz, 2012). Three prebiotics were represented, including oligofructose (Lewis et al., 
2005a; Lewis et al., 2005b), fructooligosaccharide (Madeo and Whitlick, 1999), and lactulose 
(Licht and Maltz, 2012), whereas the synbiotics, or combined prebiotic and probiotic, contained 
FOS and either Sacchromyces boulardii and Bacillus coagulans (Spielholz, 2011) or 
Lactobacillus acidophilus and Bifidobacterium (Madeo and Whitlick, 1999). Prebiotic dosage 
varied from one g/d (Spielholz, 2011) to 32.4 g/d (Madeo and Whitlick, 1999), and while 
supplementation occured during antibiotic administration in all cases, endpoints ranged from 
seven days following antibiotic cessation (Lewis et al., 2005b) to 30 days following symptom 
abatement (Lewis et al., 2005a). Two studies did not define a clear endpoint (Licht and Maltz, 
2012; Madeo and Whitlick, 1999). 
Risk of bias 
The risk of bias for the included experimental studies is summarized in Figure 3.2. The 
risk of selection bias was generally low in the three RCTs (Lewis et al., 2005a; Lewis et al., 
2005b; Madeo and Whitlick, 1999) except for a high risk in allocation concealment for a trial 
that contradicted an intention-to-treat (ITT) analysis by excluding patients after randomization 
(Lewis et al., 2005b). A low risk of bias was also observed for performance bias (blinding of 
participants and personnel), detection bias (blinding of outcome assessment), and other bias in 
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the RCTs (Lewis et al., 2005a; Lewis et al., 2005b; Madeo and Whitlick, 1999). The synbiotic 
intervention was not controlled and, therefore, possesses a high risk of selection, performance, or 
detection bias (Spielholz, 2011). The risk of attrition bias was either unclear (Lewis et al., 2005a; 
Madeo and Whitlick, 1999) or high (Lewis et al., 2005b) for all studies, and reflect the removal 
of patients during the study period (Lewis et al., 2005b) and unclear handling of non-compliant, 
early-discharge, or deceased patient data (Lewis et al., 2005a; Madeo and Whitlick, 1999) 
(Spielholz, 2011). An unclear (Lewis et al., 2005a; Lewis et al., 2005b) and high risk of bias 
(Madeo and Whitlick, 1999; Spielholz, 2011) were noted for selective reporting as well. 
Reporting bias was affected by inconsistencies in data presentation (Lewis et al., 2005a; Lewis et 
al., 2005b; Spielholz, 2011), and failure to remark on critical outcomes described in the protocol 
(Madeo and Whitlick, 1999). 
Efficacy of prebiotics for CDAD prevention 
The safety and efficacy of prebiotic therapy for all included studies is shown in Table 
3.2. Table 3.3 contains summary statistics for four studies (Lewis et al., 2005a; Lewis et al., 
2005b; Licht and Maltz, 2012; Madeo and Whitlick, 1999), as the synbiotic study did not include 
a control group for comparative analysis (Spielholz, 2011). Notably, the single group cohort 
exhibited very low diarrhea (5%) and CDAD (0.8%) prevalence following preventive synbiotic 
therapy.  
Among the three prebiotic studies that examined both the presence of diarrhea and C. 
difficile colonization (Lewis et al., 2005a; Lewis et al., 2005b; Licht and Maltz, 2012), pooled 
data measured CDAD in 99/767 (12.9%) patients. Prevalence was lower in the prebiotic group, 
as 35/374 (9.4%) supplemented patients experienced CDAD vs 64/393 (16.3%) of patients in the 
control groups (OR 0.5, 95% CI 0.3 to 0.8; P=0.005). The trial that evaluated separate prebiotic 
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and synbiotic therapies was excluded from these analyses as authors deviated from their protocol 
and did not disclose whether C. difficile was responsible for the diarrhea observed in the control 
and synbiotic groups (Madeo and Whitlick, 1999); however, the absence of diarrhea among 
patients receiving FOS is promising, albeit not statistically different from the placebo group (OR 
0.2, 95% CI 0.01 to 4.00; P=0.3). 
A meta-analysis of the three CDAD studies revealed a significant level of heterogeneity 
(I2=64%) across the three studies, but the lower prevalence of CDAD among prebiotic patients 
was not retained when data were applied to a random effects model (Figure 3.3). 
Adverse events  
Two prebiotic studies did not report adverse events (Licht and Maltz, 2012; Madeo and 
Whitlick, 1999) and the uncontrolled trial confirmed synbiotic tolerability, with minor GI side 
effects reported by seven participants (Spielholz, 2011). The trials that reported severe adverse 
events did not identify C. difficile as the primary cause of death in any of the 25 cases (Lewis et 
al., 2005a; Lewis et al., 2005b). Fatality rates did not differ between groups (4.5% vs 4.1%, OR 
1.1, NNTH=12; P=0.8), nor did defecatory frequency, abdominal pain, or bloating.  
DISCUSSION  
The present systematic review summarizes the results of five randomized and non-
randomized studies that examined the efficacy and safety of prebiotic consumption for CDAD 
prevention among susceptible adults. Two studies did not report any adverse events (Licht and 
Maltz, 2012; Madeo and Whitlick, 1999), and two studies (Lewis et al., 2005a; Lewis et al., 
2005b) did not indicate that any adverse events were related to the intervention, or differed 
between prebiotic and control groups. The decreased CDAD prevalence observed in the prebiotic 
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group was not statistically significant, and despite a lack of increased harm, any clinical benefit 
potentially afforded by prebiotics remains uncertain.  
The authors of four studies (Lewis et al., 2005a; Licht and Maltz, 2012; Madeo and 
Whitlick, 1999; Spielholz, 2011) claimed that a prebiotic or synbiotic may be effective, but only 
two studies reported a significant benefit (Lewis et al., 2005a; Licht and Maltz, 2012). Although 
Spielholz et al. (Spielholz, 2011) showed a low prevalence of diarrhea among their unilaterally 
synbiotic-supplemented patients, the study could not confirm efficacy, as it did not employ an 
appropriate control group for comparison. Similarly, for the FOS and synbiotic study, which 
reported diarrhea in less than 10% of participants, the marginal incidence within the control 
group precludes the ability to validate the study objectives (Madeo and Whitlick, 1999). Notably, 
this study was published two years before the first hypervirulent NAP1 C. difficile outbreak in 
2001, during which time disease prevalence was historically low (McDonald et al., 2006). In 
contrast to the other study by the same authors, which showed an attenuated relapse rate among 
oligofructose supplemented patients (Lewis et al., 2005a), the larger CDAD and antibiotic-
associated diarrhea (AAD) trial was unique in its assertion that prebiotics may lack the efficacy 
to reduce AAD (Lewis et al., 2005b). In patients who were recently prescribed various broad-
spectrum antibiotics, oligofructose was unable to prevent CDAD and AAD. The authors 
suggested that their exclusion of high-risk candidates (including those with gastrointestinal 
disease, impaired immunity, diabetes, or the inability to provide consent) was the most plausible 
explanation for the unexpectedly low CDAD incidence, and perhaps the lack of efficacy shown 
in this study.  
Further explanations for the lack of measurable variation between groups include the 
possibility that the prescribed antibiotics abrogated any possible advantages afforded by the 
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prebiotic, or that the duration of prebiotic intervention was inadequate to produce a significant 
effect. Interestingly, the studies that reported specified medications showed efficacy with 
patients exclusively treated with metronidazole and vancomycin (Lewis et al., 2005a), but not 
broad spectrum antibiotics (Lewis et al., 2005b). The variety of broad spectrum antibiotics 
employed in this particular trial may have decreased the selectivity of FOS to stimulate the 
growth of beneficial bacteria by impairing the metabolism of the intestinal microbiota (Lewis et 
al., 2005b). The relationship between antibiotic type and CDAD development is unclear in the 
current literature due to the presence of conflicting reports. 
The limitations of this systematic review include the small number and size of current 
studies and differences in design and outcome assessment. However, low data availability for 
this topic necessitated liberal inclusion criteria. Articles that were considered, although not 
ultimately selected for inclusion in this review, were eliminated due to the presence of perceived 
confounds or the exclusion of critical study parameters and, generally, did not reflect preferences 
in overall study design and quality (Rhim, 2008). 
Methodological and clinical diversity contraindicated complete meta-analysis for all 
studies, as treatment durations, delivery methods, dosages, products, and trial populations varied 
substantially. The meta-analysis performed on the three studies that assessed CDAD (Lewis et 
al., 2005a; Lewis et al., 2005b; Licht and Maltz, 2012) detected moderate to substantial 
heterogeneity, which was not unexpected given the low number of entries and dissimilarities 
among interventions, but suggests that the observed inconsistencies cannot be attributed to 
chance.  
Prebiotics enhance the growth of beneficial GI bacteria, reduce luminal pH, modulate 
immunity, and may restore a protective microbial phenotype within the colon (Slavin, 2013). 
60 
 
Restructuring the microbiota may directly prevent C. difficile adherence through colonization 
resistance, enhance endogenous protection mechanisms, or antagonize toxin production (Seekatz 
and Young, 2014). Reviews of existing literature attribute many of the potential benefits of 
prebiotic supplementation to its ability to increase healthful bacteria, most notably, bifidobacteria 
(Patel and Goyal, 2012; Slavin, 2013). In trials that performed fecal bacterial analysis, elevated 
bifidobacteria in stool cultures from both subsets of oligofructose-supplemented patients were 
observed, and may validate this theory (Lewis et al., 2005a; Lewis et al., 2005b). These results 
are in agreement with previously established research (Gibson et al., 1995; Rao, 2001).  
While the general aims of newer therapies, including prebiotics, probiotics, and fecal 
microbiota transplants (FMT) are similar, the aversiveness, uncertainty, and costs associated with 
FMT are not compatible with preventive care. The dietary interventions are more sustainable, 
and despite differences in research quantity and quality, prebiotics and probiotics are comparable 
in terms of heterogeneity and positive symptom improvement (Goldenberg et al., 2013; Johnston 
et al., 2012). It appears that each possess different advantages; the fact that probiotics are 
ingested as live microorganisms confers a very specific contribution to the bacterial community, 
but severely complicates their processing and storage requirements, as they may be subjected to 
premature environmental or digestive degradation (Corona-Hernandez et al., 2013).  
CONCLUSIONS  
While the administration of prebiotics may be an effective and safe method of decreasing 
CDAD prevalence among adults receiving antibiotics, the scarcity of relevant publications in this 
field, methodological and clinical diversity across studies, and low quality of available evidence 
warrants further investigation. Future work may benefit from evaluating both prophylactic and 
therapeutic prebiotic options against other emerging intervention methods. Additional clinical 
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trials are needed to appropriately evaluate efficacy using multiple types of prebiotics, eludicate 












































































Figure 3.1. PRISMA Flow Diagram. The PRIMSA diagram describes the search and 
selection process applied during the systematic review. 
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Figure 3.2. Risk of bias graph: review authors' judgements about each risk of bias item presented 
as percentages across all included experimental studies. Attrition bias and reporting bias were of 








































































































































































































































































































































CHAPTER 4: IDENTIFYING RISK FACTORS AND MALNUTRITION IN PATIENTS 




Clostridium difficile-associated disease (CDAD) is a life-threatening illness that is 
primarily associated with healthcare delivery systems. Infection is precipitated by the disruption 
of gastrointestinal microbiota, subsequent loss of colonization resistance, and contact with 
resilient endogenous or exogenous bacterial spores. CDAD selectively affects elderly individuals 
with antibiotic and healthcare exposure, yet the validity of additional risk factors is debated 
within the literature.  
The primary aim of this research was to evaluate the relationship between malnutrition 
and CDAD in a high-risk patient group, measure the relative contributions of various predictor 
variables, and assess patient outcomes. A secondary aim was to develop an efficient CDAD 
screening process that quickly and accurately identified susceptible patients and informed the 
preparation of a future interventional trial. 
A one-month preliminary study was undertaken to assess CDAD risk factors among adult 
inpatients at Carle Foundation Hospital (CFH) in Urbana, IL; six risk factors were selected 
(advanced age, admission from another healthcare facility, recent hospitalization, recent 
antibiotic use, and a history of diarrhea and CDAD within the previous year), which were 
positively correlated with CDAD prevalence. The risk factors identified in the preliminary study 
then were used to stratify records from all adult inpatient admissions throughout 2014 for use in 
the primary study.  
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Records from patients with four or more risk factors were classified as high-risk, and 
were retained to investigate the relationship between malnutrition, CDAD, and outcomes in the 
primary study. Among high-risk patients, both malnutrition and malnutrition risk were 
individually associated with elevated CDAD (OR 2.62, 95% CI 1.78 to 3.87; P<0.0001 and OR 
1.65, 95% CI 1.22 to 2.23; P=0.001, respectively). However, multiple regression identified only 
previous CDAD diagnosis, age ≥ 65, a nutrition consultation request, and Body Mass Index 
(BMI) as significant predictors of CDAD diagnosis. Neither malnutrition nor CDAD were 
individually associated with increased mortality, but among CDAD patients, those who were also 
malnourished experienced significantly higher mortality within 30 days of discharge than 
patients with CDAD alone (OR 5.49, 95% CI 2.50 to 12.04; P<0.0001).  
INTRODUCTION 
Within the last few decades, the developed world has experienced a profound increase in 
both the incidence and severity of Clostridium difficile-associated disease (CDAD), which 
accounts for nearly 500,000 infections and 15,000 deaths each year in the United States alone 
(Lessa et al., 2015). C. difficile has outpaced methicillin-resistant Staphylococcus aureus 
(MRSA) as the most common healthcare pathogen, and is currently the leading cause of 
gastroenteritis-related deaths (Miller et al., 2011). International concerns about antibiotic 
resistance and the emergence of hypervirulent C. difficile strains in the United States, Europe, 
and Canada, have warranted the reevaluation of CDAD treatment standards. Recent estimates 
indicate that 30-50% of antibiotics prescribed within hospitals and over 50% of those prescribed 
by outpatient facilities are either unnecessary or inappropriate. Paradoxically, antibiotic use, 
which enables opportunistic colonization by C. difficile, is the first line of treatment for CDAD. 
However, this problematic elimination of microbial diversity encourages future pathological 
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colonization (Pérez-Cobas et al., 2014), and even specific and narrow-spectrum antibiotics may 
not eradicate C. difficile spores. Some studies have suggested that antibiotic treatment is the main 
cause of CDAD recurrence, a phenomenon observed in approximately one in five successfully 
treated individuals, an estimated 83,000 first time recurrences each year (Shields et al., 2015). 
The waning effectiveness of current medications and high recurrence rates among previously 
treated patients highlight the need for non-antibiotic and prophylactic alternatives.   
In recent years, microbiome-based research has provided considerable insight into the 
complex interactions involving nutrition, infection, and immunity; systematic manipulation of 
the microbiome through either pharmaceutical or dietary means could have vast implications for 
human health and represent a safe and invaluable alternative to conventional therapies for the 
treatment or prevention of CDAD. The connection between malnutrition and disease acquisition 
is not a new concept. The 1968 publication, Interactions of Nutrition and Infection, described 
numerous studies that demonstrated enhanced susceptibility to intestinal pathogens with 
nutritional deficiency and elevated morbidity and mortality among malnourished individuals 
(Scrimshaw, 1968). Additionally, malnutrition has been associated with excessive costs, 
comorbidities, complications, readmissions, and an extended length of stay (LOS) (Agarwal et 
al., 2013; Corkins et al., 2014; Correia and Waitzberg, 2003; Lim et al., 2012; Marco et al., 
2011). Importantly, increased LOS and readmission among malnourished patients could prolong 
healthcare exposure and favor the development of healthcare-associated infections (HAI). 
 To date, the few publications that address nutritional status and CDAD are mostly 
correlative or preliminary in nature. In addition, the disease has predominantly been studied in 
medically unremarkable hospital-dwelling populations rather than the specific groups it is known 
to affect. The purpose of this retrospective review is to determine whether malnutrition affects 
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CDAD risk, validate well-established CDAD risk factors within our patient population (Cooper 
et al., 2013), assess patient outcomes, and begin to identify individuals that would most likely 
benefit from future clinical intervention.  
METHODS 
Study Design and Patient Sample 
Research was conducted at Carle Foundation Hospital (CFH), a 393-bed regional care 
hospital, in collaboration with the University of Illinois. Prior to the primary study, a preliminary 
investigation was undertaken to validate risk factor selection among the hospital inpatient 
population. Upon request, the CFH Biomedical Research Center provided data from all adult 
inpatient admissions within the month of January, 2013. Each patient was assessed for the 
presence of six predetermined risk factors (advanced age, admission from another hospital unit 
or healthcare facility, hospitalization within 90 days of the current hospitalization, a history of 
diarrhea within one year prior to this hospitalization, and a documented CDAD diagnosis within 
one year prior to this hospitalization) upon admission and later CDAD acquisition. 
The primary study utilized electronic data from all CFH adult inpatient admissions 
between January 2014 and December 2014. The decision to retrieve data based upon a set 
duration, rather than sample size, is consistent with medical chart review literature (Worster and 
Haines, 2004); the timeline was designed to account for the marked regional (Argamany et al., 
2015) and seasonal variations (Brown et al., 2013; Gilca et al., 2012) in CDAD prevalence.  
To validate the stratification of high-risk and low-risk groups, all inpatient data for 
individuals 18 years and older were evaluated by the number of risk factors each patient 
possessed and whether CDAD was acquired. When evaluating further aims, including those 
related to malnutrition and CDAD, patient outcomes, and CDAD severity, only adult inpatients 
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with four or more risk factors (patients designated as belonging to the high-risk group) were 
included. Due to the recurrent nature of CDAD and the potential for patients to incur multiple 
hospital visits throughout the year, all encounters with patients classified as high-risk during the 
study period were reviewed. Pediatric patients and outpatients were omitted from the study, but 
no further exclusions were made based upon primary diagnosis, comorbidity, or nutritional 
status.  
Study variables 
Patient files were searched for basic demographic information using the hospital’s 
electronic medical record (EMR) system, as well as variables related to risk assessment, 
nutritional status, and CDAD acquisition within 30 days of hospital discharge. Malnutrition was 
identified by the presence of relevant ICD-9 codes, including those for unspecified protein-
calorie malnutrition (263.9), cachexia (799.4), sarcopenia (728.2), and less common types of 
malnutrition (261, 262, 263, 263.1, and 263.8). In addition to malnutrition as a documented 
diagnosis, BMI, weight, requests for nutrition consultation, and information specific to the 
parameters set by AND/ASPEN (insufficient energy intake, weight loss, loss of muscle mass, 
loss of subcutaneous fat, edema, and decreased functional status) were requested (White et al., 
2012). Further variables of interest included primary diagnoses, medication history, CDAD 
recurrence, and potential markers of CDAD severity (leukocyte counts, creatinine levels, the 
need for emergency GI surgery, death due to CDAD, and 30-day all-cause mortality).  
Data retrieval and analysis  
All patient data were obtained through RedCap, a secure web application used to build 
and manage databases and de-identify clinical data. Differences among groups were calculated 
using T-tests for continuous variables and chi-squared tests and odds ratios (OR) for categorical 
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variables. Multiple logistic regression was used to assess the relationship between predictor 
variables and the dichotomous dependent variable using the most parsimonious model to retain 
appropriate statistical power and minimize potential bias. The limit for statistical significance 
was set at P<0.05. 
RESULTS 
Preliminary 2013 Study 
The preliminary study data provided by the Biomedical Research Center included 10,569 
adult inpatient admissions throughout the month of January 2013. Patients were classified as 
high-risk if they possessed more than half of the selected risk factors (four or more). The high-
risk group consisted of 193 people (1.8% of all adult admissions), but represented approximately 
half of all CDAD patients. The results are shown in Table 4.1. A diagnostic evaluation indicated 
that the proposed screening criteria for patients at high risk of acquiring CDAD exhibited low 
sensitivity (49.4%) and high specificity (98.9%). These data suggested that the population would 
be adequate for the proposed year-long primary study, and that the six designated risk factors 
were appropriate indicators of CDAD risk. A protocol for the primary study was submitted to the 
CFH Institutional Review Board, and accepted.  
Primary 2014 Study  
During the primary observation period, a total of 68,251 adult patients were admitted to 
CFH. As in the preliminary study, records were electronically retrieved and separated into low-
risk (66,974) and high-risk (1,277) groups. Patients were ultimately classified by their highest 
risk factor value across encounters to maintain data uniformity and prevent investigator bias. The 
selection and continued use of the risk factors was validated among primary study patients, as the 
prevalence of CDAD diagnosis increased proportionally with CDAD risk (Figure 4.1); although 
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the proportion of high-risk patients to total inpatients remained similar to earlier results from the 
preliminary study (1.9%), the high-risk designation identified 78.3% of all CDAD patients 
within the 2014 study period and appeared to predict increased odds of CDAD diagnosis (OR 
232, 95% CI 176 to 307; P<0.0001), as well as 30 day all-cause mortality (OR 11.3, 95% CI 9.5 
to 13.3; P<0.0001). Results are represented in Table 4.2. The sensitivity and specificity of the 
risk factor screening were 78.3% and 98.5%, respectively. 
The high-risk sample, which was utilized for the remaining study aims, contained 1,277 
patients and represented 8,279 encounters. The most common risk factor was a history of recent 
hospitalization (98.9% of patients), followed by a history of recent antibiotic use, and age ≥65. 
The prevalence of the six selected risk factors within the high-risk study sample is summarized 
in Table 4.3.  
Demographic information for patients at high-risk of acquiring CDAD is represented in 
Table 4.4. In general, the group contained more female than male records, but equal gender 
proportions between the CDAD-positive and CDAD-negative groups. Patients that developed 
CDAD during the observation period were generally younger (65.1 vs 74.7, P<0.0001), had a 
lower BMI (26.8 vs 28.1 kg/m2, P=0.02), and possessed more risk factors than patients without 
the diagnosis (4.6 vs 4.1, P<0.0001). Similarly, CDAD patients accumulated more 
hospitalizations than controls (7.7 vs 6.1, P=0.0004). 
Within the year, 238 (18.6%) patients within the sample acquired CDAD, and among 
these cases, 139 (10.9%) experienced CDAD recurrence. As expected, CDAD risk was 
associated with CDAD incidence and CDAD recurrence (P<0.00001; Table 4.5). 
Malnutrition, identified by ICD-9 code, was only documented for 133 (10.4%) patients. 
However, the odds of acquiring CDAD was 2.6 times higher for patients diagnosed with 
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malnutrition than for those without a malnutrition diagnosis (Table 4.6, 95% CI 1.8 to 3.9; 
P<0.0001). Similarly, according to nutrition consultation requests, CDAD was more prevalent 
among patients with high perceived-nutrition risk than patients with no perceived risk (OR 1.7, 
95% CI 1.2 to 2.2; P=0.001). Malnutrition was also associated with CDAD recurrence, as 
patients without a malnutrition diagnosis were more likely to be CDAD negative (83.2% vs 
65.4%) and less likely to experience recurrence (9.3% vs 24.8%) than their malnourished 
counterparts (P<0.00001).  
Disparities in CDAD acquisition differed across BMI groups with decreased odds among 
overweight and obese patients (Table 4.7). No significant difference was observed between the 
underweight and normal patient groups. Interestingly, malnourished patients were represented 
within all BMI groups (24 patients with an underweight BMI, 52 with a normal BMI, 21 with an 
overweight BMI, and 34 with an obese BMI). Height and weight data were unavailable for the 
remaining two malnourished patients. 
Lastly, to better assess the contributions of each predictor variable, multiple logistic 
regression analysis was performed. Among high-risk patients, the only independent variables 
from the univariate analysis that remained significant included a previous CDAD diagnosis, age 
≥65, nutrition consultation requests, and BMI (Table 4.8). Neither malnutrition nor CDAD were 
individually associated with increased mortality, but taken together, malnourished CDAD 
patients had significantly higher mortality within 30 days of discharge (Table 4.9). 
DISCUSSION 
While the results of this study differ significantly from the available literature due to 
initial stratification by patient risk, both risk factor and prevalence data remained consistent 
among high-risk patients between the preliminary and primary study. Expectedly, CDAD was far 
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more prevalent in our high-risk sample (18.6%) than in recent approximations of the national 
average of 1.4-3.4% for all inpatients (Steiner et al., 2014; Zacharioudakis et al., 2015), but the 
low cumulative prevalence of CDAD (including patients from both the high and low risk groups) 
at CFH in 2014 (0.44%) is remarkable, and more difficult to explain. It is possible that CDAD 
went undiagnosed among low-risk patients, as people who are younger, or become infected 
without predisposing history, often experience less aggressive symptoms that may not merit 
hospitalization, let alone physician follow-up. The low prevalence observed in this study may 
also be a result of tracking individual high-risk patients, rather than reporting separate 
encounters, which was implemented to prevent overestimating incidence and prevalence due to 
inevitable treatment failure and recurrence. Furthermore, long-term (or at least repeated) patient 
assessment was necessary for detecting recurrent cases, and is more consistent with the format of 
the anticipated clinical intervention this review was meant to inform. 
Alternatively, the low detection rate of iatrogenic malnutrition in this patient sample 
likely reflects a systemic and well-documented problem among healthcare institutions, more than 
atypical study design. Underdiagnosis of malnutrition has repeatedly been described by others 
(Barker et al., 2011; Gout et al., 2009) and represents an inability to identify malnourished 
patients, exacerbated by a lack of communication among healthcare providers and inconsistent 
reporting (Silver et al., 2018). Malnutrition is estimated to affect between 30-60% of hospitalized 
adults and elderly (Holst et al., 2013), which greatly exceeds the 10.4% of high-risk CFH 
patients diagnosed by the appropriate ICD-9 code. Further investigation into comparable data 
sets from recent years would be necessary to identify possible causes of error or variation. 
As a retrospective study, we were unable to account for CDAD-positive patients who did 
not return to CFH for diagnosis. CDAD is regularly treated in long-term care facilities and 
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outpatient settings, and for many people, severe GI symptoms may not prompt or necessitate 
hospitalization. Patients that may have sought care elsewhere were considered CDAD-negative 
for the purpose of this data set. In addition, the timing of this project coincided with the 
nationwide transfer to an EMR system in 2014 and could contribute to the high frequency of 
missing data within this set. Variables that were not addressed in hospital records included 
insufficient energy intake, handgrip strength as a measure of functional status, and differentiation 
between muscle and fat mass. 
In this study, electronic diagnosis of malnutrition was primarily determined by the 
presence of ICD-9 code 263.9. This particular code represents unspecified protein-calorie 
malnutrition, which is the most commonly assigned malnutrition code. Additional codes for 
cachexia (799.4), sarcopenia (728.2), and other types of malnutrition (261, 262, 263, 263.1, 
263.8) were included in the query, but did not identify any additional subjects. Importantly, ICD-
9 codes are obtained by physician assessment, and do not include input from designated nutrition 
professionals, regardless of malnutrition screening results, perceived risk, or whether a nutrition 
consultation was ordered. ICD-9 codes are known to severely underestimate malnutrition 
prevalence. A review of 227 cancer patients revealed that malnutrition prevalence estimates 
varied among sources and assessors. Estimates within the sample ranged from 8.8% based upon 
BMI and 9.3% based upon physician-assigned ICD-9 codes, to 26% based upon dietitian 
assessments (Platek et al., 2011). The kappa coefficient revealed a weak agreement between 
dietician diagnosis and physician ICD-9 codes (kappa=0.28), and fair strength of agreement 
between BMI and ICD-9 codes (kappa= 0.38). These data suggest that the identification of 
malnutrition by ICD-9 code is only marginally more reliable than diagnosis by BMI alone.  
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Obesity has previously been associated with decreased GI microbiota diversity (Kapur 
and Nagaraja, 2017), which is associated with predisposition to disease. Most research indicates 
that obesity causes low-level inflammation and metabolic dysfunction (Gregor and Hotamisligil, 
2011), but there is some evidence to suggest that obesity could be protective due to the secretion 
of anti-inflammatory interleukin-1 receptor antagonist (IL-1RA) by leptin (Gabay et al., 2001). 
In contrast to the negative correlation between BMI and CDAD detected by this study, others 
have either failed to find an association between obesity and CDAD risk (Ciricillo et al., 2016; 
Punni et al., 2015), or have reported increased risk (Bishara et al., 2013; Leung et al., 2013; 
Mulki et al., 2017). Methodological differences regarding case and control matching, regression, 
inclusion criteria, and disease classification (community-associated CDAD vs healthcare-
associated CDAD) likely affected reported outcomes.  
In order to address the disparity between observed and expected malnutrition prevalence 
in the current study, perceived malnutrition risk was inferred by the presence or absence of a 
nutrition consultation request within each patient file. As nutritional consultations are initiated 
only by the presence of tube feeding, an affirmative response to patient questions involving 
recent and significant unintentional weight loss at admission, or by physician request, the high 
perceived-risk category likely identified most malnourished patients, but also contained a 
substantial portion of false positives. In a multi-site study of 1,330 participants, the malnutrition 
screening tool (MST) accurately identified 71% of malnutrition cases while the other 29% were 
found to be adequately nourished (Phillips and Zechariah, 2016).  
The intent to retrospectively evaluate malnutrition using ASPEN/AND criteria was 
precluded by inconsistencies in electronic data reporting, incomplete patient charts, and 
otherwise unmeasured or unavailable parameters. Edema and weight loss were the only two 
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ASPEN/AND criteria reported, and missing weight data prevented the necessary calculation for 
loss over time. Furthermore, the presence of either edema or weight loss can obscure the 
detection of the other, especially without clinical context and being able to physically observe 
the patient.  
The findings from both the regression analysis and mortality analysis were unanticipated, 
as they failed to approximate previous work by other investigators that showed increased LOS 
and mortality among malnourished patients (Wong et al., 2009), and higher malnutrition and 
mortality rates, more extensive antibiotic use, and a longer LOS among CDAD patients (Fry et 
al., 2010; Monge et al., 2013). Although dissimilarities can be attributed to the stratification of 
the sample and low prevalence of malnutrition diagnoses, the possibility that malnutrition 
contributes to CDAD risk, but closely models another significant factor or group of significant 
risk factors cannot be eliminated. The selected model, however, was well-fitted, as indicated by 
the insignificant Hosmer-Lemeshow statistic, high coefficient of determination (R2), and low 
Variance Inflation Factors for all included variables, which suggested that observed proportions 
did not differ from expected proportions, 70% of the variation in the dependent variable was 
accounted for by the predictors, and multicollinearity was not a critical detraction from the 
regression results.  
CONCLUSION 
Several publications have listed malnutrition as a risk factor for CDAD, yet support for 
this claim within the primary literature is limited. In this stratified sample of high risk 
hospitalized adults, there was no significant association between CDAD and malnutrition 
following regression analysis. Although immediate nutritional interventions for CDAD 
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prevention may not yet be advisable at this time, further research regarding malnutrition 
identification and diagnosis, as well as its potential implications for human health, are warranted.    
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Figure 4.1. Predetermined Risk Factors (RF) predict Clostridium difficile-associated disease 
(CDAD) acquisition among high-risk patients during the 2014 primary study period. Columns 
represent the percentage of patients with a total of 4, 5, and 6 risk factors who were diagnosed 
with CDAD during the study period. The percentage of patients with a CDAD diagnosis 



















Table 4.1.  Positive association between CDAD risk and CDAD acquisition during 
preliminary study 
Risk Factors N CDAD prevalence1  
0 4,696 0 (0) 
1 3,015 8 (0.27) 
2 2,039 24 (1.18) 
3 626  48 (7.67) 
4 156 44 (28.2) 
5 32 29 (90.6) 
6 5 5 (100.0) 
Risk factor prevalence among patients diagnosed with Clostridium difficile-associated disease 
(CDAD) during the preliminary study period (January 2013). The first column represents the 
total number of risk factors possessed by study subjects. The second and third columns indicate 
the total number of patients represented by a given risk factor, and the percentage of patients 
diagnosed with CDAD for each risk factor, respectively. Values within the parenthesis represent 
the percentage of patients that developed CDAD per risk factor. 








Table 4.2. CDAD prevalence and patient death with risk factor stratification model. 
Risk 
Stratification 
N CDAD1  Deaths1 
Low-risk 66,974 66 (0.10) 1,024 (1.53) 
High-risk 1,277 238 (18.6) 190 (14.9) 
Risk stratification of all patients admitted throughout 2014 into low-risk (1-3 risk factors) and 
high-risk (4-6 risk factors) groups. Patients in the high-risk group had greater odds of being 
diagnosed with Clostridium difficile-associated disease (CDAD) (OR 232.2, 95% CI 175.6 to 
307.1; P <0.0001) and death (OR 11.3, 95% CI 9.54 to 13.3; P <0.0001). 









Table 4.3. Prevalence1 of Clostridium difficile-associated disease (CDAD) risk factors 
among the primary study sample. 
Risk Factors Total (percentage) of study sample with risk factor 
Hospitalized within 90 days2 1,263 (98.9) 
Antibiotics within 90 days2 1,251 (98.0) 
Age ≥ 65 yr† 1,124 (88.0) 
History of diarrhea within previous year3 892 (69.9) 
Admit from another facility 616 (48.2) 
Diagnosis of CDAD within the previous year3 298 (23.3) 
 All risk factors cumulative and specific to patient identifiers. 
 1. Prevalence expressed as percentage of patients with risk factor. 
 2. Risk factor was possessed within 90 days before patient entry into the hospital. 








Table 4.4. Demographic information of primary study participants 
Patient Characteristic CDAD Cases (n=238) ‡ Controls (n=1,039) 
Age (SD) 65.1 (18.7)* 74.7 (11.2) 
Sex (%)   
Male 94 (39.5%) 411 (39.6%) 
Female 144 (60.5%) 628 (60.4%) 
Number of Hospitalizations 
(SD) 
7.74 (6.50)* 6.13 (5.41) 
Risk Factor Total (SD) 4.62 (0.66)* 4.10 (0.31) 
BMI 26.8 (7.89)* 28.1 (7.51) 
*Compared with controls: P<0.05 








† Among the high-risk study sample, advanced age patients were evenly distributed by sex, and comprised 87.9% 
and 88.0% of the male and female patients, respectively.  
 












X2 P value 
4 Risk Factors 
n=1,052 
939 (89.3) 60 (5.70) 53 (5.04) 290 <0.00001 
5 Risk Factors 
n=199 
97 (48.7) 29 (14.6) 73 (36.7)   
6 Risk Factors 
n=26 
3 (11.5) 10 (38.5) 13 (50.0)   
Each risk factor is expressed by outcomes across each row.  
Patients were assigned to a risk group based on their highest total represented throughout the 
study period. 
1. CDAD negative: Represents patients who did not develop CDAD within the study period; all 
values within the column are presented as n (%). 
2. Incident CDAD: Represents patients who developed a single case of CDAD within the study 
period; all values within the column are presented as n (%). 
 3. Recurrent CDAD: Represents patients who developed >1 separate case of CDAD within the 
study period; all values within the column are presented as n (%). 
 
 
Table 4.6. Results of univariate analysis of potential risk factors. 
Variable Odds Ratio 95% CI P value 
Age ≥65 yr 0.08 0.06 to 0.12 <0.0001 
History of diarrhea 3.60 2.40 to 5.39 <0.0001 
Previous CDAD diagnosis 114 70.0 to 187 <0.0001 
Malnutrition 2.62 1.78 to 3.87 <0.0001 
Nutrition consultation request 1.71 1.27 to 2.30 0.0004 
Admitted from healthcare facility 0.65 0.49 to 0.86 0.0029 
Recent antibiotic use 0.54 0.23 to 1.24 0.14 
Recent hospitalization 0.92 0.26 to 3.27 0.89 
Among the high-risk patient sample, a history of diarrhea, previous Clostridium difficile-
associated disease (CDAD) diagnosis, malnutrition, and request for nutrition consultation were 
associated with increased odds of obtaining a CDAD diagnosis within the current study, while 
advanced age (≥65 years) and admission from a healthcare facility were associated with 
decreased odds. Recent antibiotic use and hospitalization did not significantly affect the odds of 







Table 4.7. CDAD risk varies by BMI classification 
Variable Odds Ratio 95% CI P value 
Underweight vs normal 1.31 0.75 to 2.31 0.35 
Overweight vs normal 0.68 0.47 to 0.98 0.04 
Obese vs normal 0.65 0.45 to 0.93 0.02 
All individual comparisons relative to normal Body Mass Index (BMI); underweight BMI<18.5 
kg/m2; normal BMI 18.5-24.9 kg/m2; overweight BMI 25-29.9 kg/m2; obese BMI≥30 kg/m2. 
Overweight and obese patients had lower odds of obtaining a Clostridium difficile-associated 
disease (CDAD) diagnosis than patients with a normal BMI; no significant difference between 




Table 4.8. Results of Multiple Logistic Regression Model 
Variable Coefficient SE OR 
Estimate 
95% CI Wald x2    P 
value 
Intercept -2.22 0.57 - - - - 
Nutrition consultation 
request 
0.53 0.26 1.70 1.20-2.83 4.14 0.04 
Age ≥65 yr -0.84 0.29 0.43 0.24-0.80 8.14 0.004 
Previous CDAD diagnosis 4.71 0.28 111 64.7-192 289 <0.0001 
BMI -0.04 0.02 0.96 0.94-0.99 5.69 0.02 
Significant predictor variables for Clostridium difficile-associated disease (CDAD) diagnosis in 
the current study included previous CDAD diagnosis, a nutrition consult request, advanced age 







Table 4.9 Mortality within 30 days of patient discharge 
Variable Odds Ratio 95% CI P value 
CDAD vs control 0.90 0.60 to 1.36 0.63 
Malnutrition vs control 1.53 0.97 to 2.41 0.07 
Malnutrition and CDAD vs CDAD only 5.49 2.50 to 12.0 <0.0001 
Neither Clostridium difficile-associated disease (CDAD) nor malnutrition were individually 
associated with mortality, but among patients with CDAD, malnutrition increased the odds of 
death within 30 days of patient discharge. 
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CHAPTER 5: ASSESSING RISK FACTORS AND MALNUTRITION IN 





Clostridium difficile-associated disease (CDAD) is a highly communicable and 
potentially lethal healthcare infection, and a significant burden on the U.S. healthcare system. A 
critical aspect of infectious disease management and prevention is the detection of patient risk 
factors, which can later be incorporated into medical interventions. In this chapter, we will 
retrospectively evaluate several previously-identified risk factors in a high-risk inpatient sample 
over the course of a year. As a follow-up to a 2014 CDAD surveillance study, results will be 
validated using a comparable data set from 2016, and will be assessed for changes over time.  
Preliminary data indicate that nutritional status and CDAD development are interrelated, 
and that supplementing malnourished patients may relieve symptoms and restore resiliency 
within the GI tract. To test this hypothesis, patient records were stratified into risk-based groups 
following assessment of the six selected risk factors from our prior study—advanced age, 
admission from a healthcare facility, recent hospitalization, antibiotic use, a history of diarrhea, 
and a previous CDAD diagnosis. Patients with four or more risk factors were classified as high-
risk and their records were retained for further analysis. As in 2014, numerical patient risk factor 
totals were directly proportional to CDAD diagnosis in 2016 (P<0.00001). The use of the six risk 




In 2016, 84,641 patients were admitted to CFH, which included 447 (0.53%) CDAD 
patients and 1,240 (1.47%) deaths within 30 days of hospital discharge. The high-risk criteria 
identified 973 patients, 173 CDAD patients, and 184 deaths within 30 days of hospital discharge. 
Malnutrition (10.4% vs 14.7%, P=0.002), mortality (14.9% vs 18.9%, P=0.01), and nutrition 
consultation requests (27.3% vs 47.3%, P<0.00001) increased between 2014 and 2016, but 
CDAD prevalence remained unchanged among high-risk patients (18.6% vs 17.8%, P=0.60). 
The two data sets produced similar results for risk factor prevalence, all demographic 
variables except for BMI, and all potential predictor variables during univariate analysis, 
including malnutrition (OR 2.04, 95% CI 1.35 to 3.07; P=0.0007). After regression analysis, 
only nutrition consultation requests (OR 1.96, 95% CI 1.24 to 3.10; P=0.004) and previous 
CDAD diagnosis remained significant predictors of CDAD among high-risk patients in 2016 
(OR 53.0, 95% CI 32.7 to 85.6; P<0.0001). 
The current study validated most of the findings from 2014, but the data did not support 
the counterintuitively decreased CDAD odds among overweight and obese inpatients. As 
expected, the selected risk factors predicted outcomes, and could be easily integrated into clinical 
practice or used to inform future interventions. The regression model indicated that malnutrition 
was not a significant predictor of CDAD among high-risk patients after accounting for more 
influential independent variables, such as a previous CDAD diagnosis. Further work is needed to 
elucidate the nature of the indirect relationship between malnutrition and CDAD and gain greater 
insights into the determinants of CDAD acquisition. 
INTRODUCTION 
Within the last twenty years, escalations in morbidity and mortality have primarily been 
attributed to the development of antibiotic-resistant organisms and hypervirulent C. difficile 
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strains. As such, infection control measures, which include the implementation of national 
surveillance programs, novel disinfection techniques, and antibiotic stewardship, have primarily 
fixated on environmental and external contributors to disease. 
 More recently, the popularization of microbiome research has drawn the focus inward. 
The importance of host-pathogen interaction is exemplified by a series of unique risk factors that 
confer susceptibility to CDAD in a manner that is both disproportionate, yet predictable.  
Research has consistently shown age to be one of the most critical risk factors for CDAD 
development, as it relates to both bacterial acquisition and CDAD-related mortality (Moshkowitz 
et al., 2007). Among hospitalized patients aged 65 years and older, interactions between the 
pathogen and host are often mediated by a combination of polypharmacy, reduced gastric 
acidity, immune senescence, increased intestinal transit time, and homogeneity of the intestinal 
microbiota (Asempa and Nicolau, 2017). Collectively, these manifestations of normal ageing can 
have detrimental health outcomes.  
The prevalence of CDAD, which is nearly nine times more common in patients over the 
age of 65, is expected to rise precipitously as the U.S. population ages (Lessa et al., 2015). By 
the year 2030, this age group will comprise over 20% of the population, a larger proportion than 
ever before (Ortman et al., 2014). Elderly patients are not only more susceptible to CDAD, but 
statistically less resilient. Patients aged 65 years and older account for over 90% of CDAD 
deaths, and one in nine cases proves fatal within 30 days of diagnosis (Kochanek, 2011).  
In addition to CDAD, many other pathologies are known to systematically affect older 
populations. Malnutrition affects approximately 60% of hospitalized people over age 65 (Mudge 
et al., 2011), and clinical improvements following nutritional supplementation have been 




Study Design and Patient Sample 
Research was conducted at Carle Foundation Hospital (CFH), a 393-bed regional care 
hospital, in collaboration with the University of Illinois. In 2014, an investigation was 
undertaken to validate risk factor selection among the hospital inpatient population. For the 
current study, all CFH adult inpatient admissions between January 2016 and December 2016 
were assessed for the presence of the six predetermined risk factors from 2014 (advanced age, 
admission from another hospital unit or healthcare facility, hospitalization within 90 days of the 
current hospitalization, a history of diarrhea within one year prior to this hospitalization, and a 
documented CDAD diagnosis within one year prior to this hospitalization) upon admission. 
The decision to retrieve data based upon a set duration is consistent with medical chart review 
literature (Worster and Haines, 2004) and the timeline was designed to account for the marked 
regional (Argamany et al., 2015) and seasonal variations (Brown et al., 2013; Gilca et al., 2012) 
in CDAD prevalence.  
Electronic medical records were first evaluated by the number of risk factors each patient 
possessed, and were subsequently stratified into high-risk and low-risk groups. Adult inpatients 
with four or more risk factors were designated as high-risk patients, and all encounters with 
patients classified as high-risk during the study period were reviewed to account for potential 
recurrence. Pediatric patients and outpatients were omitted from the study, but no further 
exclusions were made based upon primary diagnosis, comorbidity, or nutritional status.  
Study variables 
Patient files were electronically searched for basic demographic information, as well as 
variables related to risk assessment, nutritional status, CDAD acquisition within 30 days of 
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hospital discharge, CDAD severity, and 30-day all-cause mortality. Malnutrition was identified 
by the presence of relevant ICD-10 codes, including those for Kwashiorkor (E40), nutritional 
Marasmus (E41), marasmic Kwashiorkor (E42), unspecified severe protein-calorie malnutrition 
(E43), protein-calorie malnutrition of moderate and mild degree (E44), and unspecified protein-
calorie malnutrition (E46). In addition to malnutrition as a documented diagnosis, BMI, weight, 
requests for nutrition consultations, and information specific to the parameters set forth by the 
AND/ASPEN consensus statement (insufficient energy intake, weight loss, loss of muscle mass, 
loss of subcutaneous fat, edema, and decreased functional status) were requested (White et al., 
2012). Primary diagnoses, medication history, CDAD recurrence, and potential markers of 
CDAD severity (leukocyte counts, creatinine levels, the need for emergency GI surgery, death 
due to CDAD, and 30-day all-cause mortality) were collected to evaluate patient outcomes.  
Data retrieval and analysis  
Data were obtained through RedCap, a secure web application used to build and manage 
databases and de-identify clinical data. Differences between groups were calculated using T-tests 
for continuous variables and chi-squared tests and OR for categorical variables. Multiple logistic 
regression was used to assess the relationship between predictor variables and the dichotomous 
dependent variable using the most parsimonious model to retain appropriate statistical power and 
minimize potential bias. The limit for statistical significance was set at P<0.05. 
RESULTS 
2016 Data 
CFH admitted 84,641 patients in 2016, but only 973 were at high-risk for acquiring 
CDAD. Among the high-risk patients, 173 developed CDAD, 143 were diagnosed with 
malnutrition, and 184 died within 30 days of hospital discharge. In contrast, a lower proportion 
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of both CDAD prevalence and deaths were observed among the 83,668 low-risk patients 
admitted within the same year (Table 5.1). Although the high-risk designation represented only 
1.2% of all inpatients, it captured nearly 40% of all CDAD patients. The sensitivity and 
specificity of the risk factor screening were 38.7% and 99.1%, respectively. 
The prevalence of the six risk factors used to categorize high-risk patients is summarized 
in Table 5.2. As in 2014, an increasing number of CDAD risk factors was positively correlated 
with CDAD development in 2016 (P<0.00001). Patients who possessed only four risk factors 
were predominantly CDAD negative (88.8%), whereas patients who possessed six risk factors 
were far more likely to obtain a CDAD diagnosis (76.2%) (Figure 5.1).  
As in 2014, 2016 assessment of the high-risk demographics revealed that patients who 
developed CDAD throughout the study period were younger (68.2 vs 75.0 years, P<0.0001), 
required more hospitalizations (3.92 vs 2.44, P<0.0001), and possessed a higher number of 
CDAD risk factors (4.57 vs 4.11, P<0.0001) than their CDAD-negative counterparts (Table 5.3). 
However, there was no significant difference in gender (58.4% vs 55.3% female, P=0.41) or 
BMI between cases and controls (27.9 vs 28.4 kg/m2, P=0.46). 
Univariate analyses of several published risk factors were performed to help elucidate 
possible determinants of CDAD development in high-risk patients (Table 5.4). Previous CDAD 
diagnosis (OR 52.3, 95% CI 32.5 to 84.0; P<0.0001), a history of diarrhea (OR 2.78, 95% CI 
1.91 to 4.03; P<0.0001), a request for nutrition consultation (OR 1.94, 95% CI 1.38 to 2.71; 
P<0.0001), and malnutrition (OR 2.04, 95% CI 1.35 to 3.07; P=0.0007) increased the odds of 
CDAD diagnosis, while decreased odds were calculated for advanced age (OR 0.18, 95% CI 
0.12 to 0.27; P<0.0001) and admission from a healthcare facility (OR 0.42, 95% CI 0.30 to 0.58; 
P<0.0001).  Neither recent antibiotic use (OR 2.36, 95% CI 0.71 to 7.80; P=0.16) nor recent 
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hospitalization  (OR 1.30, 95% CI 0.29 to 5.87; P=0.73) affected CDAD odds. Following 
univariate analysis, multiple logistic regression analysis was conducted to explore the 
contributions of each individual predictor variable; only requests for nutrition consultations and 
previous CDAD diagnosis produced significant contributions to the model (Table 5.5). No 
interaction between malnutrition and BMI was observed. 
2014 and 2016 comparison 
A similar proportion of CDAD cases in high-risk patients were documented in 2016 and 
2014 (17.8% vs 18.6%, P=0.60), although the 2016 data set contained fewer high-risk patients 
overall (973 vs 1,277). Nutrition consultations were conducted more frequently (47.3% vs 
27.3%, P<0.00001) and a higher proportion of malnourished patients were detected (14.7% vs 
10.4%, P=0.002) in 2016 than in 2014. Figure 5.2 depicts comparisons for CDAD and 
malnutrition prevalence, as well as mortality, between the two data sets. There was no difference 
between the two years in the proportion of CDAD-positive patients provided with nutrition 
consultations (P=0.49) or diagnosed with malnutrition (P=0.24). 
 As before, the most common risk factors among the high-risk group in 2016 included 
recent hospitalization, antibiotic use, and advanced age, whereas the rarest risk factor was again 
a previous CDAD diagnosis. Fewer CDAD patients were successfully identified by risk-factor 
evaluation in 2016, as only 38.7% of inpatients who developed CDAD were included in the 
high-risk group, compared to 78.3% in 2014. While the high-risk group contained a similar 
proportion of CDAD-positive cases between the years, the three-fold increase in CDAD cases 
among the low-risk group in 2016 severely depreciated the current sensitivity estimate. 
Importantly, in both years, the high-risk designation appeared to predict both CDAD 
development and mortality. 
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 All demographic variables between cases and controls between 2014 and 2016 were 
consistent except for total hospitalizations and BMI. While patients with CDAD were 
hospitalized more frequently than their uninfected counterparts during both years, fewer 
hospitalizations were reported in 2016 overall. Additionally, in the 2016 data set, BMI did not 
differ between patients with CDAD and their uninfected counterparts, which is a critical 
departure from the lower BMI observed in conjunction with CDAD in 2014 (26.8 CDAD vs 28.1 
control; P=0.02). BMI values rose insignificantly for both groups between 2014 and 2016 (27.8 
in 2014 vs 28.3 in 2016, P=0.14), and more specifically from 26.8 to 27.9 for CDAD patients 
(P=0.16) and from 28.1 to 28.4 for controls (P=0.36). Furthermore, the decreased odds of CDAD 
measured for overweight and obese patients in 2014 were no longer seen in the current study 
(Table 5.6). 
The same potential risk factors showed significance in univariate analyses between 2014 
and 2016 and produced similar (though not identical) OR values. Regression analysis identified 
previous CDAD diagnosis and a request for nutrition consultation as significant predictors for 
both data sets, yet neither BMI nor advanced age were retained in 2016.  
In regard to mortality, 2014 and 2016 data varied considerably. All-cause 30-day 
mortality increased between 2014 and 2016 for high-risk patients (14.9% vs 18.9%, P=0.01), and 
was associated with malnutrition (OR 1.78, 95% CI 1.18 to 2.67; P=0.006), but not CDAD (OR 
0.80, 95% CI 0.51 to 1.24; P=0.3) in 2016. Conversely, neither malnutrition nor CDAD were 
individually associated with mortality in 2014, yet malnutrition was associated with elevated 
mortality specifically among CDAD patients; this relationship was absent in the 2016 data set 




The 2016 follow-up study was designed, in part, due to updates in electronic medical 
record reporting requirements through the American Recovery and Reinvestment Act, as well as 
inconsistencies between our 2014 primary study results, preliminary research, and the existing 
literature. However, the results from the 2014 and 2016 CFH data sets were predominantly 
uniform. The current data set contained fewer high risk patients than the comparable data set 
from 2014, despite having more inpatient admissions overall. Risk factor selection was designed 
to identify patients who would most benefit from future study interventions, and was based on 
the need to rapidly and reliably identify patients at-risk for CDAD before bacterial exposure 
could occur. Although the same six predetermined risk factors were used to identify potential 
CDAD patients, sensitivity of the screening fell from 78.2% in 2014 to 38.7% in 2016.  
Interestingly, CDAD prevalence increased among low-risk patients, from 0.10% in 2014 
to 0.33% in 2016, but not among patients in the high-risk group. Nevertheless, the total 2016 
CDAD prevalence for CFH, including patients from both risk groups, remained low (0.53%) in 
comparison with the national average of 1.4-3.4% (Steiner et al., 2014; Zacharioudakis et al., 
2015). 
Although low-risk patients exhibited a higher proportion of CDAD in 2016 than in 2014, 
fewer deaths occurred than were expected based on the earlier data set. It is possible that 
increased disease prevalence and slightly decreased mortality reflect a change in CDAD 
transmission, infectivity, and virulence patterns. Two of the selected factors used to stratify high-
risk patients included recent hospitalization and admission from another facility. In the last few 
years, many studies have reported on the presence of CDAD beyond its canonical hospital (or 
even long-term care facility) setting as the appearance of CDAD cases in the community have 
become more widespread. While “healthcare-associated infection” is now generally preferred to 
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“hospital-associated infection”, it should be noted that these terms are not interchangeable, and 
that many infections classified as community-associated are, in fact, still associated with 
healthcare exposure. In a 2013 study of community-associated CDAD, 82% of respondents 
experienced at least one visit to an outpatient healthcare setting such as a doctor’s or dentist’s 
office or dialysis clinic within 12 weeks before diagnosis (Chitnis et al., 2013).  
In addition to their named transmission environments, differences in community-
associated and healthcare-associated CDAD include infectivity, toxigenicity, patient selection, 
and outcomes. Community-associated CDAD often affects people who are younger and have no 
recent antibiotic exposure—people who were previously thought to be at low risk for infection. 
A 2015 surveillance article contrasted the 13.5% first-recurrence rate and 1.3% death rate of 
community-associated CDAD with the 20.9% first-recurrence rate and 9.3% death rate of 
healthcare-associated cases, and concluded that community-associated cases are less likely to 
cause recurrence or death; these outcomes were not entirely mediated by host selection either, as 
healthcare-associated isolates more commonly produced binary toxin and represented 
hypervirulent strains (Lessa et al., 2015). One possibility for the results of our 2016 study 
involves the pervasiveness of community-associated vs healthcare-associated CDAD by risk 
group. The low mortality despite elevated CDAD prevalence exhibited by patients in the low-
risk group may represent less lethal community-associated cases, whereas the high-risk patients 
would more likely be afflicted with healthcare-associated CDAD due to admission from other 
facilities and recent hospitalization. This hypothesis is supported by the aforementioned risk 
factor prevalence and increase in mortality exclusively observed in the high-risk group. Although 
CDAD was not individually associated with death, the possibility that it is interacting with some 
other variable (or set of variables) cannot be eliminated.  
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Another uncertain aspect of our 2016 study is whether the values obtained for nutrition 
consultation requests and malnutrition diagnoses reflect an actual increase in prevalence, 
increased malnutrition awareness among staff (which thereby initiated more requests for 
consultations), or improved compliance and documentation. Records from 2016 proved to be 
more thorough for certain parameters, and contained fewer missing values than in 2014. For 
instance, patients for whom no height and weight information were available decreased from 
nearly 5% of patients in 2014 to approximately 0.5% of patients just two years later. However, as 
in 2014, it seems unlikely that all malnourished patients within the sample were appropriately 
diagnosed due to the uncharacteristically low prevalence of malnutrition within the data set. 
Nutrition literature estimates that one in three patients is malnourished upon hospital admission 
(Barker et al., 2011), and that nutritional status tends to decline throughout the hospital stay 
(Somanchi et al., 2011). Statistics for elderly patients are particularly disconcerting. A Canadian 
tertiary care center reported that 69% of their study sample (with a mean age of 66 years) was 
malnourished, with 30% classified as “severely malnourished” (Singh et al., 2006). Similarly, a 
Welsh study from 2013 indicated that 44% of hospitalized patients over the age of 60 years were 
malnourished, and that nutritional status was associated with mortality, LOS, and discharge 
destination (Rasheed and Woods, 2013). 
Furthermore, significant discrepancies between malnutrition identification and 
documentation have been reported. Weight loss, appetite, oral intake, and functional status were 
documented for less than one-third of the malnourished patients in the Canadian tertiary care 
study (Singh et al., 2006), while earlier research reported that only 96 of 200 (48%) 
malnourished hospitalized patients had any record that contained nutritional information 
(McWhirter and Pennington, 1994). There is evidence of improved malnutrition documentation 
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within the last few years, as well as potential for future progress. A preliminary intervention 
confirmed that specific malnutrition education for hospital healthcare providers effectively 
enhanced EMR reporting of malnourished/high-risk patients from 26.7% to 38.3% within three 
months (Silver et al., 2018). Another collaborative project of 105 institutions showed a 
significant increase in malnutrition diagnosis from 4.0%-4.9% between 2014 and 2015 (Tobert et 
al., 2018). These recent statistics are improvements upon 2010 HCUP data, which reported 
diagnosis among only 3.2% of patients (Corkins et al., 2014), and are consistent with the 
increased prevalence of malnutrition diagnosis observed between the 2014 and 2016 CFH 
reviews.  
Although the prevalence of malnutrition diagnosis among all CFH inpatients cannot be 
inferred with current data, 14.7% of the high-risk patient sample was assigned a malnutrition-
related ICD-10 code within the EMR. It seems appropriate that the high-risk group contained a 
greater proportion of diagnoses than estimates from general inpatients, yet the available literature 
indicates that even this result is likely an underestimate. The extreme disparity between the 
prevalence of malnutrition among hospitalized patients and prevalence of identified and 
documented malnutrition diagnoses is a systemic issue, and requires further investigation. 
 Unlike earlier results, in 2016 BMI was non-significant between cases and controls. 
BMI increased for both groups between 2014 and 2016, but was 3.4-fold higher for CDAD 
patients. The proportion of malnourished patients in each BMI group was similar across the two 
data sets. For both years, overweight and obese patients made up slightly over 60% of the high-
risk group, while underweight patients accounted for only approximately 6% of the total. Other 
studies have reported a range of values for overweight and obesity prevalence among 
hospitalized patients, from 45% of adult inpatients in a Norwegian study (Følling et al., 2014) to 
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74.5% in the American Health Cost and Utilization Project Nationwide Inpatient Sample 
(Akinyemiju et al., 2016). The CDC Behavioral Risk Factor Surveillance System described 
26.3% and 27.5% of elderly Americans as obese in 2014 and 2016, respectively. 
Increased odds of underweight patients developing CDAD did not reach statistical 
significance for either year, and the decreased odds of CDAD measured for overweight and 
obese patients in 2014 were not observed with the 2016 data; importantly, this retrospective 
study design cannot separate cause from consequence. Some studies have documented improved 
outcomes among overweight and obese hospital patients, such as decreased mortality and LOS, 
in conjunction with certain conditions in a phenomenon referred to as “the obesity paradox” 
(Yamauchi et al., 2014). The association is counterintuitive, as obesity also has been linked to 
many cardiovascular and metabolic disorders. Additionally, there is some evidence to suggest 
that obesity-related conditions may become more pronounced with age (Følling et al., 2014).  
Most of the potential risk factors identified by univariate analysis were not significant 
predictors in the logistic regression model. While malnutrition and CDAD were correlated in 
both the 2014 and 2016 data sets, it was not determined to be an independent predictor of CDAD 
in either study, and may have been overwhelmed by more influential predictors. Variance 
Inflation Factors for the regression model were below two for every predictor variable, which 
indicates that collinearity was within an acceptable range, and did not play a pivotal role in our 
study. Additional model fit statistics, such as the residual chi-square test and the Hosmer and 
Lemeshow Test also yielded insignificant values, and suggests that the regression model was 
appropriate. 
As in 2014, there were several limitations to our study, including patients who did not 
return to CFH for diagnosis or treatment and were, therefore, presumed to be CDAD-negative, 
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inconsistent and incomplete data reporting, and an inability to determine disease causation 
through this type of retrospective analysis. The main differences between the 2014 and 2016 data 
sets were the transition from ICD-9 to ICD-10 coding and inconsistencies regarding the criteria 
that constitute an individual hospitalization, which dictated the removal of patient hospitalization 
totals as a parameter from the regression model to avoid undue influence.  
Results from both studies indicate that overall CDAD prevalence at CFH was low in 
comparison with the national average, and that mortality rates, even among high-risk CDAD 
patients, which approximated 14% in 2014 and 16% in 2016, were well within other hospital 
estimates of 9%-37% (Walters et al., 2014; Hota et al., 2012). The vast majority of deaths within 
the high-risk group occurred among elderly patients; patients over 65 years accounted for 91% 
and 94% of the total high-risk deaths in 2014 and 2016, respectively, which is consistent with 
existing studies (Kochanek et al., 2011). Although the high-risk group contained a greater 
proportion of malnutrition diagnoses than studies assessing diagnosis among all hospitalized 
patients, the percentage of patients identified as malnourished by ICD-10 code in the 2016 study 
likely represents only half of the actual malnourished patient population (Barker et al., 2011). 
Underdiagnosis of malnutrition is hardly unique to CFH, but increased identification or 
documentation of both nutrition consultations and malnutrition diagnoses between 2014 and 
2016 are indicative of significant improvement. 
CONCLUSION 
The selected CDAD risk factors first identified in the preliminary 2013 data and validated 
by the primary 2014 and 2016 studies could be easily integrated into the EMR to automatically 
alert hospital staff of high-risk patients before bacterial exposure occurs and effectively help 
redirect resources toward these patients. Similar patient screening procedures have been 
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successfully implemented for other lethal and expensive diseases, such as sepsis, and have 
decreased disease-related fatalities, conserved costs, and improved patient outcomes (Jones et al., 
2015). However, due to the uniquely infectious and transmissible nature of C. difficile, isolating 
high-risk patients, enacting contact precautions, and providing careful monitoring would not only 
protect the selected patients, but the entire hospitalized population.  
Although local infectious disease surveillance is vital and can help direct opportunities for future 
intervention, it cannot delineate cause and effect. Interventional studies designed to ameliorate 
malnutrition are not immediately warranted for CDAD prevention or treatment, yet are unlikely 
to cause significant harm. Further research is needed to better understand the nature of the 
association between malnutrition and CDAD, which appear to be indirectly related among high-
risk inpatients. 
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Figure 5.1. Predetermined Risk Factors (RF) predict Clostridium difficile-associated disease 
(CDAD) acquisition among high-risk patients during the 2016 primary study period. Columns 
represent the percentage of patients with a total of 4, 5, and 6 risk factors who were diagnosed 
with CDAD during the study period. The percentage of patients with a CDAD diagnosis 


































Figure 5.2. No difference was observed in Clostridium difficile-associated disease (CDAD) 
prevalence in high risk patients between 2014 and 2016 (p=0.57), but malnutrition (p=0.002) and 






Table 5.1. CDAD prevalence and patient death with risk factor stratification model. 
Risk 
Stratification 
N CDAD1  Deaths1 
Low-risk 83,668 274 (0.33) 1056 (1.26) 
High-risk 973 173 (17.8) 184 (18.9) 
Risk stratification of all patients into low risk (1-3 risk factors) and high risk (4-6 risk factors) 
groups. Patients in the high-risk group had greater odds of being diagnosed with Clostridium 
difficile-associated disease (CDAD) (OR 65.8, 95% CI 53.7 to 80.6; P<0.0001) or death (OR 
18.2, 95% CI 15.4 to 21.7; P<0.0001). 









Table 5.2. Prevalence1 of Clostridium difficile-associated disease (CDAD) risk factors 
among high-risk patients 
Risk Factors Total (percentage) of study sample with risk factor 
Hospitalized within 90 days2 959 (98.6) 
Antibiotics within 90 days2 938 (96.4) 
Age ≥ 65 yr§ 851 (87.5) 
Admit from another facility 613 (63.0) 
History of diarrhea within previous year3 547 (56.2) 
Diagnosis of CDAD within the previous year3 221 (22.7) 
 All risk factors cumulative and specific to patient identifiers. 
 1. Prevalence expressed as percentage of patients with risk factor. 
 2. Risk factor was possessed within 90 days before patient entry into the hospital. 







Table 5.3. Demographic information of high-risk patients 
Patient Characteristic CDAD Cases (n=173)** Controls (n=800) 
Age (SD) 68.2 (18.1)* 75.0 (12.1) 
Sex (%)   
Male 72 (41.6%) 358 (44.8%) 
Female 101 (58.4%) 442 (55.3%) 
Number of Hospitalizations 
(SD) 
3.92 (3.21)* 2.44 (1.68) 
Risk Factor Total (SD) 4.57 (0.66)* 4.11 (0.33) 
BMI 27.9 (8.03) 28.4 (7.84) 
*Compared with controls: P<0.05 











§ Among the high-risk study sample, advanced age patients were evenly distributed by sex, and comprised 89.8% 
and 85.6% of the male and female patients, respectively (P=0.53).  
 




Table 5.4. Results of univariate analysis of potential risk factors. 
Variable Odds Ratio 95% CI P value 
Age ≥65 yr 0.18 0.12 to 0.27 <0.0001 
Admitted from healthcare facility 0.42 0.30 to 0.58 <0.0001 
Previous CDAD diagnosis 52.3 32.5 to 84.0 <0.0001 
History of diarrhea 2.78 1.91 to 4.03 <0.0001 
Nutrition consultation request 1.94 1.38 to 2.71 <0.0001 
Malnutrition 2.04 1.35 to 3.07 0.0007 
Recent antibiotic use 2.36 0.71 to 7.80 0.16 
Recent hospitalization 1.30 0.29 to 5.87 0.73 
Among the high-risk patient sample, a history of diarrhea, previous Clostridium difficile-
associated disease (CDAD) diagnosis, malnutrition, and request for nutrition consultation were 
associated with increased odds of obtaining a CDAD diagnosis within the current study, while 
advanced age (≥65 years) and admission from a healthcare facility were associated with 
decreased odds. Recent antibiotic use and hospitalization did not significantly affect the odds of 
CDAD diagnosis within the high-risk group. 
 
 
Table 5.5. Results of Multiple Logistic Regression Model 
Variable Coefficient SE OR 
Estimate 
95% CI Wald 
x2 
P value 
Intercept -3.64 0.24 - - - - 
Nutrition consultation 
request 
0.67 0.23 1.96 1.24-3.10 8.19 0.004 
Previous CDAD diagnosis 3.97 0.25 53.0 32.7-85.6 262 <0.0001 
Significant predictor variables for Clostridium difficile-associated disease (CDAD) diagnosis in 
the current study included previous CDAD diagnosis and a nutrition consult request. 
 
 
Table 5.6. BMI classification does not affect Clostridium difficile-associated disease (CDAD) 
risk 
Variable Odds Ratio 95% CI P value 
Underweight vs normal 1.78 0.90 to 3.50 0.10 
Overweight vs normal 1.38 0.91 to 2.10 0.13 
Obese vs normal 0.96 0.63 to 1.47 0.85 
All individual comparisons relative to normal Body Mass Index (BMI); underweight BMI<18.5 
kg/m2; normal BMI 18.5-24.9 kg/m2; overweight BMI 25-29.9 kg/m2; obese BMI≥30 kg/m2. All 





CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
 
The interactions between diet, energy metabolism, and the microbiome are extremely 
complex, and the means by which GI epithelium, pathogens, and the microbiota mediate 
immunity is not entirely known. Acknowledging the critical nature of the gastrointestinal 
microbiota, taken together with the compromised nutritional status often observed during disease 
development and progression, makes the provision of adequate nutritional care in healthcare 
settings seem not only intuitive, but necessary.  
A 2017 article, aptly titled “Kick the Bucket” reads “…the burden of Clostridium difficile 
outpaces goals. Unless innovative approaches are tried, we risk culling elderly, 
immunosuppressed, and otherwise debilitated populations” (Delaney, 2017). Although this claim 
may initially seem hyperbolic, it makes an impassioned and convincing argument in favor of 
readdressing outdated treatment standards, and represents a reality that is bleak, but ultimately 
valid. The convergence of an ageing U.S. population large enough to precipitate an epidemic, 
increasing institutional accountability for infections (especially those viewed as preventable), 
and a lack of progress on national CDAD reduction goals set forth by both HHS (HHS, 2013) 
and the independent non-profit health-accreditation organization known as The Joint 
Commission (2018), indicates that CDAD is unlikely to improve without directed change, and 
that novel prophylactic and treatment strategies are desperately needed. 
This dissertation has reviewed the risks and costs associated with standard CDAD 
treatment, emphasized the importance of prevention due to poorer patient outcomes and 
recurrent disease, detailed a systematic review of an understudied but likely beneficial 
prophylactic solution, analyzed CDAD risk factors with a focus on malnutrition, and assessed 
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CDAD infection patterns and outcomes over time for high-risk hospital patients with the intent to 
inform future clinical interventions. This research was conducted in four parts. First, an initial 
review of the clinical and scientific literature was conducted to identify therapies that had shown 
promise in CDAD patients. From this investigation, a hypothesis about the role of prebiotics was 
constructed based on a small and heterogenous collection of clinical research regarding 
prebiotics and CDAD, but more importantly, the efficacy of prebiotics for other digestive 
diseases, and their history in animal and in vitro research.    
To determine whether a clinical study could responsibly be undertaken, the existing 
clinical research was assembled into a systematic review that centered around the PICO 
question: “Can prebiotic consumption prevent or reduce the prevalence of CDAD in adults 
receiving antibiotic treatment?” Since very few articles had evaluated prebiotic administration 
for CDAD, studies involving CDAD and synbiotics were also included, with the rationale that 
they contained prebiotics. Ultimately, it was concluded that most of the studies suggested 
prebiotic safety and efficacy, but current research could not provide the necessary evidence to 
make a valid recommendation. Although conducting a meta-analysis on three studies seemed 
like a scientific rarity, it revealed valid and critical information. The fact that only three of the 
five available studies included the desired outcome variable highlighted all of the heterogeneity 
and design flaws within the research itself. However, due to heterogeneity, a random effects 
model was deemed to be appropriate, as it was unreasonable to expect that each of these studies 
produced a uniform effect. The results of the random effects model included an OR of 0.43, a 
broad 95% confidence interval of 0.15 to 1.01, and the borderline P value of 0.05. Essentially, 
this finding was non-significant and inconclusive. Future clinical prospective trials in this area 
are necessary, as they would undoubtedly provide invaluable data on the usefulness of prebiotic 
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supplementation. Importantly, it would be necessary to intensively evaluate the study design, 
including sample size, inclusion criteria, selected outcomes, and the handling of missing data 
prior to the initiation of the trial. The existing literature would be greatly improved by current, 
well-conducted randomized controlled trials with large sample sizes and a reasonable, rather than 
excessive, number of outcome measures. In summary, although four studies claimed a prebiotic 
or synbiotic benefit, only two were statistically verified. The only conclusion that could fairly be 
asserted was that prebiotic therapy may reduce CDAD, but insufficient and low-quality evidence 
precludes the objective assessment of clinical benefit. 
While designing the 2014 retrospective review, we were working under the hypothesis 
that the disproportionate distribution of CDAD risk and prevalence would be mirrored by an 
uneven benefit derived from potential interventions. The chart reviews were designed to help 
prepare for an interventional study that would exclusively target patients who were likely to 
acquire CDAD. Prior to conducting the 2014 review, a literature search was performed and a 
one-month preliminary study was initiated to test the validity of well-known CDAD risk factors 
at CFH; due to the ubiquitousness of C. difficile spores in healthcare settings and because CDAD 
can be acquired at any time (although illness may not manifest for up to two days), it was 
imperative that study participants be recruited and begin the intervention within 48 hours of 
admission. Risk factors were selected partially due to their ability to be provided at the time of 
admission since C. difficile could be acquired in the time it would take to complete a thorough 
patient examination or return lab analyses. Results from the preliminary study showed that the 
selection of six risk factors, including advanced age, admission from a healthcare facility, recent 
hospitalization, antibiotic use, a history of diarrhea, and a previous CDAD diagnosis, seemed not 
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only adequate to detect and predict CDAD risk, but would avoid the unnecessary recruitment and 
treatment of excess patients. 
For the 2014 primary study, a full year of records was requested for all patients 
possessing four or more risk factors to prevent interference by variations in seasonal risk. CDAD 
diagnoses, primary diagnoses, variables that related to malnutrition and weight, medication 
history, and likely markers of CDAD severity were delivered through RedCap, and were then 
analyzed using unpaired t-tests, chi-squared tests, OR with 95% confidence intervals, and 
multiple logistic regression. The high-risk group consisted of 1,277 inpatients, and included 238 
CDAD positive patients, and 133 patients with diagnosed malnutrition. A total count of all low 
risk patients, including deaths and those with CDAD, was compared with the high-risk group to 
ensure that risk stratification was managed appropriately. The relative frequency of risk factors 
among high-risk patients varied from 23.4% to 98.9%. Demographics differed between cases and 
controls in all measured fields except gender.  
An odds ratio was calculated for every potential predictor variable, and all significant 
terms were considered for inclusion in the final regression model. Among high-risk patients, 
previous diarrhea, previous CDAD, malnutrition, and requests for nutrition consultation were 
associated with significantly increased odds of CDAD diagnosis, whereas advanced age and 
admission from a healthcare facility were associated with decreased odds. Regression analysis 
identified requests for nutrition consultations, advanced age, previous CDAD, and BMI as 
significant predictors of CDAD diagnosis. Neither CDAD nor malnutrition were associated with 
elevated mortality. 
As expected, CDAD prevalence was considerably higher in our high-risk patient sample 
than the national average for all patients, and as others have described, malnutrition was likely 
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underreported in our study. We were unable to control for patients who did not return to CFH, 
and inconsistencies in data reporting undermined our ability to detect malnutrition using 
AND/ASPEN criteria or assess severity beyond 30-day all-cause mortality. We specifically 
hoped to infer malnutrition diagnoses by calculating specified weight changes over time in 
conjunction with edema, but were not able to do so due to restrictions in the data set. 
This study was unique in that it only employed a high-risk group that consisted of 
unmatched CDAD patients and controls. Many retrospective studies are performed using large 
database sourcing, and may not include control patients, or match cases and controls to reduce 
confounding variables. Another difference between our work and the work of others was an 
attempt to control for reinfection, relapse, and treatment failure by tracking data for individual 
patients rather than for individual encounters. We did not gain strong support for our hypothesis 
that malnutrition is associated with CDAD diagnosis and, notably, our study design was unable 
to detect causation. 
The novel study design, while planned and necessary, became an unintended obstacle 
during the analysis and interpretation of the 2014 project, as it became increasingly apparent that 
the newly acquired results had no basis for comparison in the current literature. These 
uncertainties were only compounded by the possibility that missing observations from the 2014 
data set were an arbitrary consequence of recent electronic reporting mandates for acute care 
facilities, which were widely regarded as vague, unnecessary, and unfavorable at the time. 
Essentially, the preliminary and primary studies had provided data that were being interpreted in 
a vacuum; this played a role in the decision to undertake a second retrospective review using a 
comparable data set, but from a more recent year. 
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 The 2016 chart review was a validation study that examined the same parameters among 
high-risk patients stratified by the six risk factors derived from the 2014 preliminary study; it 
also compared study variables between the two years. Identical methods were employed to 
maintain consistency, although a few notable differences between the data represented in the two 
sets could not be addressed. Improved data reporting between 2014 and 2016 was expected, 
although it remains unclear whether this result was intentional, or driven by contemporaneous 
EMR updates, as we had initially hypothesized. 
The 2016 high-risk group contained 973 patients, including 173 CDAD patients, 143 
patients with a malnutrition diagnosis (which is definitively different from malnourished 
patients, as previously mentioned), and 184 deaths. Between 2014 and 2016, results were mostly 
similar, yielding increased confidence in the results obtained from our previous study. Although 
CDAD prevalence did not change, we observed increased malnutrition diagnoses, requests for 
nutrition consultations, and mortality among the high-risk patients. Conversely, low-risk patients 
exhibited slightly fewer deaths than would be expected based upon 2014 data, yet CDAD was 
simultaneously raised by three-fold in this group; owing to the increased CDAD prevalence and 
decreased mortality in the low-risk group, coupled with a contradictory elevation in mortality 
and equal CDAD prevalence among high-risk patients, it seemed plausible that the low-risk 
patients may have been afflicted by community-associated CDAD, which exhibits a different 
infection pattern than healthcare-associated CDAD. The only other notable differences between 
the two years were a significant difference in BMI between cases and controls, decreased odds of 
CDAD diagnosis in overweight and obese patients, and inclusion of advanced age and BMI as 
significant predictors in the regression model in 2014. 
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One of the most interesting aspects of these studies was the distribution of malnourished 
patients across all four BMI categories, which directly contradicts the popular belief that 
malnutrition only afflicts underweight individuals (or that healthcare professionals should be 
reluctant to diagnose overweight or obese individuals with malnutrition). Weight and BMI 
cannot serve as adequate indicators of nutritional status or bodily composition on their own; just 
as underweight individuals can be adequately nourished, overweight and obese individuals can 
suffer from malnutrition. 
The limitations of the validation study include inconsistencies between the methods used 
to classify “total hospitalizations”, which can be visualized by extreme differences between 2014 
and 2016 data for this particular variable. Documentation of hospitalization was noted not only 
upon admission, but also during transfer to other hospital units, and occasionally, upon the 
initiation of various procedures. It seems that multiple hospitalizations were attributed to what 
were likely single hospitalizations in 2014, and created artificially inflated totals. While the 
difference between cases and controls within the same year are likely to represent a true 
difference, the inexplicable decrease in hospitalizations between 2014 and 2016 is suspect. 
Another limitation related to the existing EMR system was the inability to access detailed 
prescribing history (e.g. which conditions the listed medications were prescribed for) and 
information regarding the resolution of prior illnesses, as these parameters were necessary for 
accurate CDAD recurrence and comorbidity assessment. 
This research has important implications for several audiences, primarily healthcare 
institutions, medical researchers and educators, and hospitalized patients, long-term care facility 
residents, and the people who care for them. The results of these studies, taken together with 
information drawn from other clinical and academic resources, indicate that environmental 
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surveillance, common-sense risk reduction, and nutrition education may all improve patient 
outcomes. The main ways in which CDAD is propagated throughout a facility are through 
environmental contact with spores, contact with infected, but not necessarily symptomatic 
individuals, and the sharing of contaminated spaces. Since the six risk factors identified by our 
chart reviews captured a high proportion of subsequent CDAD cases among less than two 
percent of all patients admitted to the hospital within each year, the introduction of an automated 
risk factor-based screening process, administered upon admission, could be used to prospectively 
recognize patients at-risk for CDAD. Positive EMR screening results could be applied 
pragmatically to redirect resources toward high-risk patients to encourage ancillary hygiene, 
antibiotic restriction, vigilant oversight, contact precautions, and patient isolation. The allocation 
of private rooms, appropriate signage, auxiliary nursing and janitorial staff, and attentive care to 
a marginal number of high-risk inpatients could have an inordinately beneficial impact on 
morbidity, mortality, operating costs, Medicare reimbursements, and facility infection rates. 
In 2008, a pilot study was initiated at Houston Methodist Hospital in response to rampant 
sepsis-induced mortality and ineffective management (Jones et al., 2015). The program was 
developed, implemented, and assessed over four years before being expanded by a federal grant 
in 2012. As screening compliance increased, fewer sepsis-related deaths occurred. The risk-
based patient screening procedure for sepsis reduced costs and mortality, and provides a clear 
precedent for early intervention within the hospital setting. 
 In addition to the timely detection of high-risk CDAD patients, the current research 
illustrates the need for systematic and standardized malnutrition screening, assessment, and 
reporting. Although minor improvements in the prevalence of diagnosis have been noted over 
time (which were supported by our 2014 and 2016 retrospective study results), increased 
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identification and documentation will not remedy systemic malnutrition without purposeful 
education and organized treatment. In the U.S. and Canada, accredited physicians, physician 
assistants, and nurses are required to complete Continuing Medical Education (CME) or a field-
specific equivalent to maintain competency and ensure they remain updated within their field. 
Nutrition-based CME credits are available online at no cost, and a 2017 study showed that these 
courses may help account for a lack of nutritional training in medical school, particularly with 
regard to lifestyle diseases (Hicks and Murano, 2017). A single one-hour online lesson was 
sufficient to increase physician knowledge of type 2 diabetes, which was a critical improvement, 
as 50% of the surveyed physicians were unable to define the purpose of Medical Nutrition 
Therapy and 85% were unfamiliar with the prevalence of diabetes in the U.S. prior to the course. 
In another study, over 95% of clinicians reported an intention to change their practice by asking 
more questions, listening more, assessing patients’ willingness to change, and adjusting 
counseling based on a patients’ willingness to change after a two-hour workshop (Sargeant et al., 
2008). However, time constraints, complacency with current skills, a lack of self-efficacy, and 
the fear of missing influential opportunities with patients impaired their ability to adopt and 
continue newly acquired practices. It remains essential that physicians are educated (and, 
perhaps, continually reeducated) on the recognition of malnutrition and evidence-based nutrition 
interventions (Tappenden et al., 2013). 
Physicians are first confronted with inadequate nutrition education in the early phases of 
their post-baccalaureate career. In an invited commentary from JAMA Internal Medicine, a third-
year Harvard medical student compared the 60 hours of cardiology delivered during a single year 
to the nine hours of nutrition education offered throughout all four years of medical school 
(Morris, 2014), and claimed that “…a poorly trained physician workforce should be viewed, in 
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and of itself, as a structural contributor to diet-related disease”. The lack of funding and trained 
and interested professors, as well as the misguided perception that nutrition is insufficiently 
science-based, contribute to curriculum decisions. Furthermore, archaic and discredited 
information, such as the use of albumin and prealbumin as the foremost indicators of nutritional 
status, is still disseminated in nursing and medical schools (Singh et al., 2006; Smith, 2017). 
Nutritional knowledge is lacking at both the highest and lowest positions on the 
healthcare spectrum, and is aggravated by the overwhelming plurality of nutrition screening 
methods, competing professional organizations and associations, unclear regulatory 
requirements, and incomplete clinical documentation. The Joint Commission began mandating 
universal malnutrition-risk screening in 1995 for all patients in acute care facilities within 24 
hours of admission (Patel et al., 2014). However, hospitals that do not seek Joint Commission 
accreditation (including CFH) are not subject to screening compliance, and may not even utilize 
a standardized and validated screening tool in favor of more subjective methods. At a basic level, 
the tool selected for screening should be appropriate for the individual in question, and may 
involve the screening setting (e.g. community, subacute, or acute care) anthropometry, age, 
functional status, and the presence of comorbidities and psychological diagnoses. Regardless of 
which tool is ultimately used or whether a facility is accredited, nutrition education is important 
for all healthcare providers, particularly front line staff and nurses responsible for screenings.  
A comprehensive nutrition care model should be adopted and sustained by all healthcare 
providers to focus on malnutrition identification, diagnosis, and documentation, as well as the 
implementation of appropriate nutritional interventions, monitoring, and communication with the 
patient and other providers up to, and following, discharge (Tappenden et al., 2013). 
Communication among providers includes both initial and intermittent nutrition screenings, 
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followed by the forwarding of positive results to a dietician, who then performs the nutritional 
assessment, appropriately transcribes any nutrition-based diagnoses into the EMR and, if 
applicable, directs nutritional intervention. Implementing a standardized workflow can provide 
more synchronous, coordinated, and holistic patient care, and in many facilities, advancements in 
technology have automated this process to enhance efficiency and reliability. 
Since it is unreasonable to dismiss a modifiable risk factor that accurately predicts both 
outcomes and costs, the overall purpose of this work was to build upon previous reports and 
examine whether nutritional intervention might be warranted for patients with an illness that is 
historically resistant to treatment. Improving options for CDAD prevention and treatment may 
ultimately require collaboration by experts from multiple disciplines, such as bioinformatics, 
bioengineering, surgery, general medicine, gastroenterology, gerontology, nursing, dietetics, 
social work, environmental sanitation, immunology, and microbiology. Until a solution is 
discovered, hospitals will remain a potential access point for people who are unable to obtain or 
wait for primary care; it is in the best interest of healthcare institutions to encourage productive 
partnerships between physicians and basic scientists, to exercise judicious antibiotic stewardship 
techniques, prescribe narrow-spectrum antibiotics whenever possible, and exercise extreme 
caution with patients who require these antibiotics, are elderly, immunosuppressed, or otherwise 
experience a disruption in their gut microbiota that endangers digestive and immune equilibrium. 
While some healthcare facilities and employer-sponsors of health insurance have cited expense 
as a reason for resisting the implementation of nutrition-based wellness programs, they are 
failing to recognize the tradeoff between the relatively minor cost of improved nutritional 
education and care, and potentially devastating costs due to unnecessary resource utilization, 
prolonged illness, and uncontrolled comorbidities (Sacks et al., 2009). Advances in technology 
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have helped facilitate the dissemination of nutrition education, and have literally paid off for 
many employers who offer employee health promotion programs. 
However, as the avenues for CDAD transmission continually increase beyond hospitals 
and other healthcare settings, preventive strategies need to evolve in order to provide adequate 
protection for both canonical and atypical CDAD patients. Approximately 345,000 CDAD cases 
occur outside of the hospital each year, which underscores the demand for affordable, accessible, 
and widespread prophylaxis (Lessa et al., 2015). The impact of nutritional status on immunity 
and gut microbial maintenance suggests that supplementation, particularly with prebiotics or 
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